clovis oncology  wikipedia clovis oncology from wikipedia the free encyclopedia jump to navigation search this article may rely excessively on sources too closely associated with the subject potentially preventing the article from being verifiable and neutral please help improve it by replacing them with more appropriate citations to reliable independent thirdparty sources december  learn how and when to remove this template message clovis oncology is a midsized pharmaceutical company which mainly markets products for treatment in oncology clovis was founded in  and is headquartered in boulder colorado the company is a publicly traded company on nasdaq under the symbol clvs  and is in the nasdaq biotechnology index with several products in its product pipeline contents  pipeline  rociletinib  rucaparib  lucitanib  references  external links pipelineedit its products include rociletinibedit the company was developing rociletinib as a treatment for nonsmall cell lung cancer a phase iii trial was completed in april  and had it been approved it would have competed with astrazenecas tagrisso osimertinib according to the company web site as of november  studies on the drug are no longer accepting new patients but clovis would continue to supply the drug to patients whose physicians had recommended continued treatment rucaparibedit rucaparib is a parp inhibitor in phase ii and iii clinical trials for advanced ovarian cancer lucitanibedit lucitanib is a vegfr inhibitor it is also an inhibitor of fgfr and fgfr and has undergone clinical trials for advanced solid tumors referencesedit  a b clovis oncology a winning or losing lottery ticket forbes  retrieved    clvs profile financeyahoocom   clovis oncology inc wwwmarketwatchcom retrieved  january    overview nbi nasdaqcom retrieved  january    clovis oncology  products  companion diagnostics clovisoncologycom  march  archived from the original on march   retrieved  january    williams sean  december  a festivus for the invest in us  its time for the airing of grievances fox business retrieved  january    wallace alicia clovis oncology stock bludgeoned after delay in cancer drug approval wwwdenverpostcom retrieved  january    clovis oncology announces regulatory update for rociletinib nda filing wwwreuterscom archived from the original on  march  retrieved  january    fda requests additional data for rociletinib in egfr tmmutant nsclc onclive  retrieved    a b investors doubt efficacy of clovis lung cancer med rociletinib shares off  april   about clovis retrieved  november    rucaparib at clovis  lucitanib at clovis  soria et al  phase iiia study evaluating the safety efficacy pharmacokinetics and pharmacodynamics of lucitanib in advanced solid tumors annals of oncology   – pmid  doiannoncmdu cs maint explicit use of et al link external linksedit clovis oncology retrieved from httpsenwikipediaorgwindexphptitleclovisoncologyoldid categories pharmaceutical companieshidden categories cs maint explicit use of et alarticles lacking reliable references from december all articles lacking reliable references navigation menu personal tools not logged intalkcontributionscreate accountlog in namespaces article talk variants views read edit view history more search navigation main pagecontentsfeatured contentcurrent eventsrandom articledonate to wikipediawikipedia store interaction helpabout wikipediacommunity portalrecent changescontact page tools what links hererelated changesupload filespecial pagespermanent linkpage informationwikidata itemcite this page printexport create a bookdownload as pdfprintable version languages français edit links this page was last edited on  june  at  text is available under the creative commons attributionsharealike license additional terms may apply by using this site you agree to the terms of use and privacy policy wikipedia® is a registered trademark of the wikimedia foundation inc a nonprofit organization privacy policy about wikipedia disclaimers contact wikipedia developers cookie statement mobile view zacks investment research downgraded clovis oncology inc nasdaqclvs to hold in a report released today headlines business technology economy personal finance menuheadlines business technology economy personal finance dont miss peet’s buys majority stake in another coffee chain walgreen records q loss as expected ebay plans to spin off paypal tibco taken private by vista equity for  billion athlon energy athl up big on buyout news dave  buster’s ipo terms set  per share home  investing  zacks investment research downgraded clovis oncology inc nasdaqclvs to hold in a report released today zacks investment research downgraded clovis oncology inc nasdaqclvs to hold in a report released today by al wild updated july   yesterday clovis oncology inc nasdaqclvs traded  higher at  the company’s day moving average is  and its day moving average is  the last closing price is up  from the day moving average compared to the sp  which has increased  over the same time  shares of the stock were exchanged down from an average trading volume of  zacks investment research has downgraded clovis oncology inc nasdaqclvs to hold in a report released on  previously on  zacks investment research reported on clovis oncology inc nasdaqclvs raised the target price from  to  at the time this indicated a possible upside of  see chart below clovis oncology inc has a  week low of  and a  week high of  the company’s market cap is currently  in addition to zacks investment research reporting its target price a total of  brokers have issued a report on the stock the consensus target price is  with  brokers rating the stock a strong buy  brokers rating the stock a buy  brokers rating the stock a hold  brokers rating the stock a underperform and finally  brokers rating the stock a sell general information about clovis oncology inc nasdaqclvs clovis oncology inc is a biopharmaceutical company focused on acquiring developing and commercializing anticancer agents in the united states europe and other international markets the companys product candidates include rociletinib rubraca rucaparib and lucitanib rucaparib is an oral small molecule poly adenosine diphosphate adpribose polymerase parp inhibitor of parp parp and parp approved as a monotherapy for the treatment of patients with deleterious breast cancer brca human genes associated with the repair of damaged deoxyribonucleic acid dna mutation germline andor somatic associated advanced ovarian cancer lucitanib is an oral inhibitor of the tyrosine kinase activity of vascular endothelial growth factor receptors vegfr  plateletderived growth factor receptors pdgfr alpha and beta and fibroblast growth factor receptors fgfr  rociletinib is an oral mutantselective inhibitor of epidermal growth factor receptor egfr receive news  ratings via email  enter your email address below to receive a concise daily summary of the latest news and analysts ratings with marketbeatcoms free daily email newsletter leave a reply cancel reply your email address will not be published required fields are marked comment name  email  website more news suncor energy inc tsesu target price lowered to  issued a report today by td securities suncor energy inc tsesu had its rocky mountain dealerships inc tserme target bumped up to  released a research note earlier today by national bank financial boasting a price of  rocky sherritt international corporation tses target price raised to  reported today by scotia capital yesterday sherritt international corporation tses traded tembec inc tsetmb target price raised to  reported today by rbc capital markets tembec inc tsetmb had its target six flags entertainment nysesix has been downgraded from neutral to underperform in a statement by macquarie research earlier today having a price of  six bmo capital markets disclosed servicenow inc nysenow bumping up its stock price target to  today in a report released on  the boeing company nyseba has been upgraded from neutral to buy in a statement by bank of america merrill lynch earlier today bank of america merrill lynch has bank of america merrill lynch downgraded silgan holdings inc ndaqslgn from buy to neutral in a report released today bank of america merrill lynch has ubs securities announced the cocacola company nyseko bumping up its stock price target to  today yesterday the cocacola company nyseko traded jp morgan upgraded rockwell automation nyserok from underweight to neutral in a statement released earlier today jp morgan has upgraded rockwell automation about breaking finance news contributors contact privacy policy copyright   breaking finance news stocks index  markets index bulletin investor alert new york markets open in market snapshot analyst ratings stocks rates funds bonds benchmarks real estate investment trusts futures american depository receipt stocks exchange traded notes warrants indexes exchange traded funds currencies crypto currencies browse stocks stocks az abcdefghijklmnopqrstuvwxyzother browse by location argentina australia austria bahamas bahrain belgium bermuda botswana brazil british virgin islands canada cayman islands chile china colombia curacao cyprus czech republic denmark egypt estonia finland france germany gibraltar greece hong kong hungary iceland india indonesia ireland isle of man israel italy japan jordan kazakhstan kuwait latvia lebanon liechtenstein lithuania luxembourg malaysia malta mauritius mexico monaco money rates morocco namibia netherlands new zealand norway oman pakistan panama peru philippines poland portugal qatar romania russia saudi arabia singapore slovakia slovenia south africa south korea spain sri lanka sweden switzerland taiwan thailand tunisia turkey ukraine united arab emirates united states venezuela western samoa log in  am edt july   marketstatecountryus new york pre marketstatecountryuk london open marketstatecountryjp tokyo closed marketstatecountryus   marketstatecountryuk   marketstatecountryjp   view all latest news newslatest aset yourself up to get the most out of retirement aeuropean stocks sell off as ubs falls tech worries weigh aprince william and kate middleton are hiring— though not for these weird five royal family jobs arightmove profit rises on ad sales abank of ireland profit falls to restart dividend ahow do i get a reverse mortgage aus tech stocks shape up for another day of selling after amazon disappoints athis city’s subway system will soon run entirely on renewable energy a‘skinny’ repeal of obamacare fails to pass in latenight senate vote aubs credit suisse profit up after strategic shift arenault firsthalf profit leaps on higher volume aftse  under pressure as bt pushed lower afrances cac  falls  dropping further in early friday trade abarclays falls  after earnings report abritish airways parent iag rises  after quarterly profit report abritish airways parent iags profit soars agermanys dax opens  lower at  afrances cac  opens  lower at  alinde profit slides on restructuring costs auks ftse  opens  lower at  loading more headlines dow quoteszigmanrealtime    nasdaq quoteszigmanrealtime    sp  quoteszigmanrealtime    kiosk   the retirementors retirement advice from our industry experts our team of financial professionals can help you plan and save for retirement then live well in it congakioskretirementorshtml    alerts congakioskalertshtml    virtual stock exchange our free stockmarket game • trade your virtual portfolio in real time • talk strategies in group discussions • find or create a game that suits you • use our learning center to improve congakioskgameshtml    location scouts housingmarket insights from our realty pros plus the latest data from realtorcom on  home markets across the us • see our complete real estate site congakioskrealestatehtml    lazy portfolios set it and forget it check out the returns on our  lazy portfolios that are made up of lowcost buyandhold index funds • how to create your own lazy portfolio congakiosklazyportfoliohtml  marketwatchcom site index topics help feedback newsroom roster media archive premium products mobile company info code of conduct corrections advertising media kit advertise locally reprints  licensing broker center your ad choices follow marketwatch rss podcasts wsjcom barrons online bigcharts virtual stock exchange financial news london wsjcom small business realtorcom mansion global copyright   marketwatch inc all rights reserved by using this site you agree to the terms of service privacy policy and cookie policy intraday data provided by six financial information and subject to terms of use historical and current endofday data provided by six financial information all quotes are in local exchange time realtime last sale data for us stock quotes reflect trades reported through nasdaq only intraday data delayed at least  minutes or per exchange requirements marketwatch top stories link to marketwatchs slice  clovis oncology inc private company information  bloomberg july    am et biotechnology company overview of clovis oncology inc snapshot people company overview clovis oncology inc a biopharmaceutical company focuses on acquiring developing and commercializing anticancer agents in the united states europe and internationally its commercial product includes rubraca rucaparib tablet an oral and small molecule poly adpribose polymerase inhibitor as monotherapy for the treatment of patients with deleterious breast cancer mutation associated advanced ovarian cancer who have been treated with two or more chemotherapies and selected for therapy by an fdaapproved companion diagnostic for rubraca the company is also involved in the ariel and ariel confirmatory trials of rucaparib as a potential maintenance therapy and treatment for ovaria clovis oncology inc a biopharmaceutical company focuses on acquiring developing and commercializing anticancer agents in the united states europe and internationally its commercial product includes rubraca rucaparib tablet an oral and small molecule poly adpribose polymerase inhibitor as monotherapy for the treatment of patients with deleterious breast cancer mutation associated advanced ovarian cancer who have been treated with two or more chemotherapies and selected for therapy by an fdaapproved companion diagnostic for rubraca the company is also involved in the ariel and ariel confirmatory trials of rucaparib as a potential maintenance therapy and treatment for ovarian cancer trial of rucaparib in prostate indications triton  a phase  singlearm study in men with metastatic castrateresistant prostate cancer and triton a phase  comparative study in men with mcrpc enrolling brca mutant and atm as well as engages in the various clinical studies for other indications it distributes its product primarily through specialty distributors and pharmacy providers to patients and health care providers the company has license agreements with pfizer inc astrazeneca uk limited advenchen laboratories llc and celgene corporation and collaboration and license agreement with les laboratoires servier clovis oncology inc was founded in  and is headquartered in boulder colorado detailed description  flatiron parkwaysuite boulder co united statesfounded in  employees phone  fax  wwwclovisoncologycom key executives for clovis oncology inc mr patrick j mahaffy ma cofounder chief executive officer president and executive director age  total annual compensation k dr gillian c iversread bsc cofounder chief regulatory officer and executive vice president of technical operations age  total annual compensation k mr daniel w muehl cpa senior vice president of finance and principal financial  accounting officer age  total annual compensation k dr lindsey rolfe bsc mb chb mrcp ffpm chief medical officer and executive vp of clinical preclinical development  pharmacovigilance age  total annual compensation k mr corwin dale hooks chief commercial officer and senior vice president age  total annual compensation k compensation as of fiscal year  clovis oncology inc key developments clovis oncology inc  special call jun   to discuss the ariel results clovis oncology inc announces topline data from confirmatory phase  ariel trial of rucaparib jun   clovis oncology inc announced topline data from the confirmatory phase  ariel trial of rucaparib which successfully achieved the primary endpoint of improved progressionfree survival pfs by investigator review in each of the three populations studied pfs was also improved in the rucaparib group compared with placebo by blinded independent central review bicr a key secondary endpoint based on these findings the company plans to submit a supplemental new drug application snda within the next four months for a secondline and later maintenance treatment indication for all women with platinumsensitive ovarian cancer who have responded to their most recent platinum therapy ariel is a doubleblind placebocontrolled phase  trial of rucaparib that enrolled  women with platinumsensitive highgrade ovarian fallopian tube or primary peritoneal cancer the primary efficacy analysis evaluated three prospectively defined molecular subgroups in a stepdown manner tumor brca mutant tbrcamut patients inclusive of germline and somatic mutations of brca hrdpositive patients including brcamutant patients and brca wildtype with high loss of heterozygosity or lohhigh patients and finally the intenttotreat population or all patients treated in ariel significant improvement in pfs in the tbrcamut patient population the most robust clinical outcomes were observed among ariel patients with a germline or somatic brca mutation n by investigator review the rucaparib arm successfully achieved statistical significance over the placebo arm for the primary endpoint of pfs with a hazard ratio of  prucaparib tablets became the first poly adpribose polymerase parp inhibitor approved by the us food and drug administration fda as monotherapy for treatment of patients with deleterious brca mutation germline andor somatic associated advanced ovarian cancer who have been treated with two or more prior chemotherapies clovis oncology seeks acquisitions jun   clovis oncology inc nasdaqgsclvs is seeking acquisitions clovis oncology is raising funds in the amount of approximately  million or approximately  million through an offering transaction clovis oncology anticipate that clovis oncology will use the net proceeds of this offering for general corporate purposes including sales and marketing expenses associated with rubraca in the united states and if approved by the ema in europe funding of our development programs general and administrative expenses acquisition or licensing of additional product candidates or businesses and working capital similar private companies by industry company name region n labs inc united states andme inc united states c tech corporation inc united states v biosciences inc united states bar biologics inc united states recent private companies transactions typedate target no transactions available in the past  months request profile update   the information and data displayed in this profile are created and managed by sp global market intelligence a division of sp global bloombergcom does not create or control the content for inquiries please contact sp global market intelligence directly by clicking here stock quotes market data is delayed at least  minutes company lookup most searched private companies company name geographic region lawyers committee for civil rights under law united states nyc inc united states the advertising council inc united states bertelsmann ag europe rush university united states sponsored financial commentaries sponsored links browse companies a b c d e f g h i j k l m n o p q r s t u v w x y z              request profile update only a company representative may request an update for the company profile documentation will be required to contact clovis oncology inc please visit wwwclovisoncologycom company data is provided by sp global market intelligence please use this form to report any data issues information missing  please enter your information in the following fields company name your name your email address your phone number type of data overview executives key developments similar companies transactions update needed all data changes require verification from public sources please include the correct value or values and a source where we can verify cancel submit your requested update has been submitted our data partners will research the update request and update the information on this page if necessary research and followup could take several weeks if you have questions you can contact them at bwwebmasterbusinessweekcom close zacks investment research downgraded clovis oncology inc nasdaqclvs to hold in a report released today headlines business technology economy personal finance menuheadlines business technology economy personal finance dont miss peet’s buys majority stake in another coffee chain walgreen records q loss as expected ebay plans to spin off paypal tibco taken private by vista equity for  billion athlon energy athl up big on buyout news dave  buster’s ipo terms set  per share home  investing  zacks investment research downgraded clovis oncology inc nasdaqclvs to hold in a report released today zacks investment research downgraded clovis oncology inc nasdaqclvs to hold in a report released today by al wild updated july   yesterday clovis oncology inc nasdaqclvs traded  higher at  the company’s day moving average is  and its day moving average is  the last closing price is up  from the day moving average compared to the sp  which has increased  over the same time  shares of the stock were exchanged down from an average trading volume of  zacks investment research has downgraded clovis oncology inc nasdaqclvs to hold in a report released on  previously on  zacks investment research reported on clovis oncology inc nasdaqclvs raised the target price from  to  at the time this indicated a possible upside of  see chart below clovis oncology inc has a  week low of  and a  week high of  the company’s market cap is currently  in addition to zacks investment research reporting its target price a total of  brokers have issued a report on the stock the consensus target price is  with  brokers rating the stock a strong buy  brokers rating the stock a buy  brokers rating the stock a hold  brokers rating the stock a underperform and finally  brokers rating the stock a sell general information about clovis oncology inc nasdaqclvs clovis oncology inc is a biopharmaceutical company focused on acquiring developing and commercializing anticancer agents in the united states europe and other international markets the companys product candidates include rociletinib rubraca rucaparib and lucitanib rucaparib is an oral small molecule poly adenosine diphosphate adpribose polymerase parp inhibitor of parp parp and parp approved as a monotherapy for the treatment of patients with deleterious breast cancer brca human genes associated with the repair of damaged deoxyribonucleic acid dna mutation germline andor somatic associated advanced ovarian cancer lucitanib is an oral inhibitor of the tyrosine kinase activity of vascular endothelial growth factor receptors vegfr  plateletderived growth factor receptors pdgfr alpha and beta and fibroblast growth factor receptors fgfr  rociletinib is an oral mutantselective inhibitor of epidermal growth factor receptor egfr receive news  ratings via email  enter your email address below to receive a concise daily summary of the latest news and analysts ratings with marketbeatcoms free daily email newsletter leave a reply cancel reply your email address will not be published required fields are marked comment name  email  website more news suncor energy inc tsesu target price lowered to  issued a report today by td securities suncor energy inc tsesu had its rocky mountain dealerships inc tserme target bumped up to  released a research note earlier today by national bank financial boasting a price of  rocky sherritt international corporation tses target price raised to  reported today by scotia capital yesterday sherritt international corporation tses traded tembec inc tsetmb target price raised to  reported today by rbc capital markets tembec inc tsetmb had its target six flags entertainment nysesix has been downgraded from neutral to underperform in a statement by macquarie research earlier today having a price of  six bmo capital markets disclosed servicenow inc nysenow bumping up its stock price target to  today in a report released on  the boeing company nyseba has been upgraded from neutral to buy in a statement by bank of america merrill lynch earlier today bank of america merrill lynch has bank of america merrill lynch downgraded silgan holdings inc ndaqslgn from buy to neutral in a report released today bank of america merrill lynch has ubs securities announced the cocacola company nyseko bumping up its stock price target to  today yesterday the cocacola company nyseko traded jp morgan upgraded rockwell automation nyserok from underweight to neutral in a statement released earlier today jp morgan has upgraded rockwell automation about breaking finance news contributors contact privacy policy copyright   breaking finance news clovis oncology  home home about clovis mission vision and values leadership products pipeline patients  caregivers business development investors  news grants  research careers contact rubraca is now approved in the us for more information please visit wwwrubracacom full us prescribing information request medical information pipeline learn more about our innovative pipeline more » patients  caregivers review the latest information about our clinical trials and find essential resources more » investors  news get uptodate financial data and read our latest news releases more » latest news view all releases » advancing the fight against cancer in our pursuit to improve the lives of people living with cancer clovis oncology is committed to realizing the promise of personalized medicines for cancer we seek to develop targeted therapies in combination with companion diagnostics to better serve patients and ensure the right drug gets to the right patient learn more about our innovative product candidates » copyright   by clovis oncology all rights reserved contact  terms of use  privacy policy  sitemap clovis oncology  home home about clovis mission vision and values leadership products pipeline patients  caregivers business development investors  news grants  research careers contact rubraca is now approved in the us for more information please visit wwwrubracacom full us prescribing information request medical information pipeline learn more about our innovative pipeline more » patients  caregivers review the latest information about our clinical trials and find essential resources more » investors  news get uptodate financial data and read our latest news releases more » latest news view all releases » advancing the fight against cancer in our pursuit to improve the lives of people living with cancer clovis oncology is committed to realizing the promise of personalized medicines for cancer we seek to develop targeted therapies in combination with companion diagnostics to better serve patients and ensure the right drug gets to the right patient learn more about our innovative product candidates » copyright   by clovis oncology all rights reserved contact  terms of use  privacy policy  sitemap clovis oncology  products back to top rubraca is now approved in the us for more information please visit wwwrubracacom full us prescribing information request medical information copyright   by clovis oncology all rights reserved contact  terms of use  privacy policy  sitemap clvs stock price  clovis oncology inc stock quote us nasdaq  marketwatch sections watchlist signup • login search bulletin us europe asia fx rates futures range d d m m m y y dow    sp     nasdaq    globaldow    gold    oil    sp  movers adp  tsco  vz  orly  ca  jci  ffiv  xl  latest newsall times eastern a prince william and kate middleton are hiring— though not for these weird five royal family jobs a set yourself up to get the most out of retirement a updated european stocks sell off as ubs falls tech worries weigh a rightmove profit rises on ad sales a how do i get a reverse mortgage a bank of ireland profit falls to restart dividend a us tech stocks shape up for another day of selling after amazon disappoints a this city’s subway system will soon run entirely on renewable energy a ‘skinny’ repeal of obamacare fails to pass in latenight senate vote a ubs credit suisse profit up after strategic shift to be replaced home investing quotes stocks united states clvs overview compare quotes stock screener earnings calendar sectors nasdaq clvs us nasdaq join td ameritrade find a broker clovis oncology inc watchlist createclvsalert after hours last updated jul    pm edt delayed quote     after hours volume k close chg chg     advanced charting d d m m m ytd y y all   vol advanced charting  vs avg volume m  day avg  m open  close   day lowhigh  day range   week lowhigh  your watchlist customize marketwatch have watchlists log in to see them here or sign up to get started create account … or log in symbol last chg chg  no items in watchlist there are currently no items in this watchlist add ticker to watchlist go to your watchlist no saved watchlists create a list of the investments you want to track create watchlist …or try this starter list uh oh something went wrong while loading watchlist go to watchlist recently viewed tickers no recent tickers visit a quote page and your recently viewed tickers will be displayed here search tickers overview profile news charts financials historical quotes analyst estimates options sec filings insiders key data open  day range     week range    market cap b shares outstanding m public float m beta  rev per employee k pe ratio na eps  yield na dividend na exdividend date na short interest m   of float shorted  average volume m performance  day   month   month  ytd   year  recent news marketwatch other dow jones clovis oncology stock price target raised to  from  at jp morgan clovis oncology stock price target raised to  from  at jp morgan jun   at  am et by tomi kilgore clovis oncology to launch  mln stock offering clovis oncology inc said on monday it plans to launch a  million stock offering the announcement follows a  surge in clovis oncology shares after the company released positive latestage trial results for cancer drug rubraca the stock offering proceeds will be used for various general purposes including sales and marketing for rubraca clovis oncology itself will be offering all shares of the common stock company shares have surged  over the last three months compared with a  rise in the sp   jun   at  pm et by emma court clovis oncology to launch  mln stock offering clovis oncology to launch  mln stock offering jun   at  pm et by emma court clovis oncology stock surges  on positive latestage cancer trial results clovis oncology inc shares surged  in premarket trade monday after the company said its latestage trial for a cancer drug met its primary endpoint and a key secondary endpoint clovis said it plans to try for food and drug administration approval for the drug rucaparib within the next four months for second line and later maintenance treatment for women with platinumsensitive ovarian cancer who have responded to their most recent platinum therapy leerink analyst michael schmidt described the latest results as bull case plays out the outcome looks to be the bestcasescenario for clvs he said adding the results look particularly impressive when compared to previous competitor data including companies like tesaro and astrazeneca  which are also developing a class of cancer drugs called parp inhibitors if approved rubraca would have the broadest label of any parp inhibitor in ovarian cancer which we think should bode well for the commercial uptake of the drug schmidt said calling the company a prime takeout candidate in three subgroups of women with ovarian fallopian tube or primary peritoneal cancer patients on rucaparib had improved progressionfree survival the phase  trials primary endpoint progressionfree survival was also improved in patient on the drug as compared with placebo a key secondary endpoint clovis oncology said the trial enrolled  women clovis oncology shares have dropped  to  over the last three months compared with a  rise in the sp   jun   at  am et by emma court clovis oncologys stock soars  premarket after positive phase  trial results clovis oncologys stock soars  premarket after positive phase  trial results jun   at  am et by tomi kilgore clovis oncology stock price target raised to  from  at jp morgan clovis oncology stock price target raised to  from  at jp morgan may   at  am et by tomi kilgore clovis oncology upgraded to overweight from neutral at jp morgan clovis oncology upgraded to overweight from neutral at jp morgan may   at  am et by tomi kilgore tesaro stock dives  after drug pricing snafu apr   at  am et by emma court morgan stanley is bullish on gambling bearish on jelly apr   at  pm et by ryan vlastelica these corporate ties will be on display at scott gottlieb’s fda commissioner confirmation hearing today apr   at  am et by emma court tesaro won’t reveal price of its ovarian cancer drug but it’ll likely be near  a month mar   at  am et by emma court opinion  tech and biotech stocks with momentum mar   at  am et by harry boxer growthstock speculators need to tap the brakes here dec   at  pm et by kevin marder  stocks to watch dec   at  pm et by harry boxer clovis oncologys stock resumes trade up  at highest closing level since nov   dec   at  pm et by tomi kilgore clovis oncologys ovarian cancer treatment gets fda ok dec   at  am et by tomi kilgore clovis oncologys stock was up  prior to trading halt dec   at  am et by tomi kilgore clovis oncologys cancer treatment rubraca gets fda approval dec   at  am et by tomi kilgore clovis oncologys stock halted for news dec   at  am et by tomi kilgore in focus the sp is better but not there yet sep   at  am et by lawrence g mcmillan charting the market the financial magazine’s graphic look at selected stock activity for the week ended june   included are oracle amd and winnebago jun   at  am et on barrons online us stocks climb as tech sector bounces back us stocks finished higher driven by gains in technology shares with the dow industrials and sp  ending at new records jun   at  pm et on the wall street journal the dark side of good news in biotech deal making is a staple of the biotech industry but betting on mergers and acquisitions is much harder than it looks for investors jun   at  am et on the wall street journal stocks to watch apple amazon rice energy valeant among the companies with shares expected to trade actively in monday’s session are apple inc and other highflying tech stocks rice energy inc and valeant pharmaceuticals international inc jun   at  am et on the wall street journal tesaro explores sale tesaro is exploring a sale according to people familiar with the matter two months after the cancertreatment developer won a key drug approval may   at  pm et on the wall street journal biotech ma trade hits a snag mar   at  am et on the wall street journal resisting the allure of gilead mar   at  am et on barrons big pharma not small investors is driving biotech values now sep   at  pm et on the wall street journal would gilead pick up tesaro’s parp sep   at  pm et on barrons new drugs for ovarian cancer patients sep   at  am et on the wall street journal stocks to watch jp morgan bank of america delphi automotive pultegroup apr   at  am et on the wall street journal fda panel opposes approval of clovis lungcancer treatment apr   at  pm et on the wall street journal us stocks rally led by energy sector nov   at  pm et on the wall street journal astrazeneca’s lungcancer drug tagrisso gets fda’s approval nov   at  pm et on the wall street journal astrazeneca gets fda approval for ovarian cancer drug dec   at  pm et on the wall street journal top biotech picks for q earnings jul   at  am et on barrons stocks to watch staples tjx urban outfitters may   at  am et on the wall street journal stocks to watch citigroup gamestop winnebago mar   at  am et on the wall street journal intercept pharmaceuticals the mother of all momentum stocks jan   at  pm et on the wall street journal healthcare stocks where to find value nov   at  am et on barrons recent news other news press releases whats in the cards for aerie aeri this earnings season aerie pharmaceuticals aeri is expected to throw light on updates on rhopressa during its secondquarter earnings call on aug  jul   at  pm et on zackscom how astrazeneca failed not once — but twice — in cancer drugs astrazeneca azn not only failed in a lung cancer trial — which had the side effect of sending rival bristolmyers squibb bmy spiraling — but its partnership with dows merck mrk appears to be an admission of defeat in the initial immunooncology race shares of astrazeneca and bristolmyers sold off in droves early thursday on the stock market today astrazeneca took a pitfall to a fivemonth low down  near  bristol too jul   at  pm et on investors business daily astrazenecas lynparza deal with merck stokes fellow parp developer clovis shares ahead  astrazenecas lynparza deal with merck stokes fellow parp developer clovis shares ahead  jul   at  pm et on seeking alpha can biomarin bmrn keep the earnings streak alive in q biomarin pharmaceutical inc bmrn is likely to see continued momentum in vimizim and kuvan sales backed by robust patient growth in q jul   at  am et on zackscom whats in store for endocyte ecyt this earnings season endocyte ecyt looks forward to shift its focus on car tcell smallmolecule drug conjugates smdcs adaptor platform the dualtargeted dna crosslinker drug ec in q jul   at  am et on zackscom aveo pharmaceuticals aveo q earnings whats in store aveo pharmaceuticals aveo depends on collaboration revenues and milestone and other payments for its top line the chmp recommendation for tivozanib maa received during the quarter was a positive jul   at  am et on zackscom biotech bonanza the next leg up biotech bonanza the next leg up jul   at  pm et on seeking alpha hershey trust co buys eagle pharmaceuticals inc momo inc clovis oncology inc sells atlassian  hershey trust co buys eagle pharmaceuticals inc momo inc clovis oncology inc sells atlassian corporation plc ametek inc nimble storage inc jul   at  pm et on gurufocuscom whats in the cards for merck kgaa mkgaf in q earnings merck kgaas mkgaf life science segment is expected to perform well following the approval of bavencio jul   at  am et on zackscom  stocks at week highs still worth buying jul   at  am et on motley fool gilead could acquire this biotech — but vertex is still better analyst gilead sciences gild could fill a hole in its portfolio by acquiring incyte incy an analyst suggested friday offering one caveat — vertex pharmaceuticals vrtx would still be a less risky bet though gilead could make a play now for incyte — to the tune of a  premium on its stock price — the no  biotech would largely be betting on the commercial success of incytes immunooncology drug epacadostat meanwhile its dealing with a jul   at  pm et on investors business daily could q surprise spike this beleaguered biotechs stock a key hepatitis c drug from gilead sciences gild could top wall streets expectations but investors will be tuning into the companys secondquarter report on july  for more hints on potential ma activity an analyst said friday gileads hepatitis c sales slipped in  and in the months following the no  biotech said it could be open to a deal especially in oncology analysts have been quick to offer up incyte incy tesaro tsro jul   at  pm et on investors business daily clovis clvs focuses on rubraca launch and label expansion we issued an updated research report on boulder cobased clovis oncology inc clvs on jul  jul   at  pm et on zackscom heres why clovis oncology inc jumped  in june jul   at  am et on motley fool this rebounding pharma stock may launch another breakout move after breakouts from biotech stocks like celgene celg clovis oncology clvs and bioverativ bivv irelandbased ethical drugs firm jazz pharmaceuticals jazz is trying to return to its former wall street glory and launch another big run the developer of specialty drugs for narcolepsy oncology pain and psychiatry earned an upgrade to its relative strength rs rating friday from  to  over  years of market history reveals that the jun   at  pm et on investors business daily gilead and vertex should join — but dont hold your breath analyst gilead sciences gild would be better off acquiring vertex pharmaceuticals vrtx than an oncology asset like tesaro tsro or incyte incy an analyst suggested friday as he lamented gileads cautious approach to mergers the no  biotech by market cap has shown interest in making an oncologycentric buy as it struggles with declining hepatitis c drug sales the hepatitis c franchise brought in north of  billion over three years but fell jun   at  pm et on investors business daily  stocks that turned  into at least  in just one year jun   at  am et on motley fool is it too late to buy clovis oncology stock jun   at  pm et on motley fool will abbvie outsmart biosimilars and can clovis win the parp race jun   at  am et on motley fool is clovis oncology a takeover candidate is clovis oncology a takeover candidate jun   at  pm et on seeking alpha technical snapshots for these biotech stocks  exelixis celldex therapeutics clovis oncology and geron technical snapshots for these biotech stocks  exelixis celldex therapeutics clovis oncology and geron jul   at  am et on pr newswire  prf clovis oncology to announce second quarter  financial results and host webcast conference call on august  clovis oncology to announce second quarter  financial results and host webcast conference call on august  jul   at  am et on businesswire  bzx clovis oncology announces exercise in full of underwriters’ option to purchase additional shares of common stock clovis oncology announces exercise in full of underwriters’ option to purchase additional shares of common stock jun   at  pm et on businesswire  bzx biopharma stock breakouts with significant developments and market activity biopharma stock breakouts with significant developments and market activity jun   at  pm et on pr newswire  prf key pharma stocks with advanced developments and breakthrough discoveries key pharma stocks with advanced developments and breakthrough discoveries jun   at  am et on pr newswire  prf clovis oncology announces upsizing and pricing of public offering of common stock clovis oncology announces upsizing and pricing of public offering of common stock jun   at  pm et on businesswire  bzx todays research reports on stocks to watch clovis oncology and valeant pharmaceuticals todays research reports on stocks to watch clovis oncology and valeant pharmaceuticals jun   at  am et on accesswire clovis oncology announces proposed offering of common stock clovis oncology announces proposed offering of common stock jun   at  pm et on businesswire  bzx sienna biopharmaceuticals appoints erle mast former cfo and cofounder of clovis oncology to board of directors sienna biopharmaceuticals appoints erle mast former cfo and cofounder of clovis oncology to board of directors jun   at  am et on globenewswire clovis oncology announces presentations at  asco annual meeting clovis oncology announces presentations at  asco annual meeting may   at  am et on businesswire  bzx investor network clovis oncology inc to host earnings call investor network clovis oncology inc to host earnings call may   at  am et on accesswire myriad genetics and clovis oncology sign agreement for use of fdaapproved bracanalysis cdxr test to identify patients with germline brca mutations for rubracar rucaparib treatment apr   at  am et on globenewswire clovis oncology to announce first quarter  financial results and host webcast conference call on may  apr   at  am et on businesswire  bzx todays research reports on biotech stocks to watch nektar therapeutics and clovis oncology apr   at  am et on accesswire research reports initiation on biotech stocks  sarepta therapeutics galena biopharma anthera pharma and clovis oncology apr   at  am et on pr newswire  prf global oncology market gains ground driven by innovative cancer treatment therapies apr   at  am et on pr newswire  prf pancreatic cancer treatment market analysis by affected region exocrine endocrine by type chemotherapy targeted therapy others by region north america europe asia pacific latin america and mea and segment forecasts    mar   at  pm et on pr newswire  prf shareholder alert law office of brodsky  smith llc announces investigation of the board of directors of clovis oncology inc  clvs mar   at  pm et on accesswire  biotech companies set for major breakouts in  mar   at  am et on pr newswire  prf biotech stocks under scanner  acadia pharma clovis oncology galena biopharma and northwest biotherapeutics feb   at  am et on pr newswire  prf clovis oncology inc clovis oncology inc is a biopharmaceutical company which focuses on acquiring developing and commercializing cancer treatments in the united states europe and other international markets the company has three product candidates in its clinical development pipeline rociletinib rucaparib and lucitani clovis oncology was founded by andrew r allen gillian c iversread patrick j mahaffy and erle t mast on april   and is headquartered in boulder co see full profile analyst ratings sell under hold over buy number of ratings  full ratings what to expect from clovis oncology following rubraca approval jun   at  pm et on benzingacom benzingas top upgrades downgrades for june   jun   at  am et on benzingacom clovis addresses some of the companys biggest controversies jun   at  pm et on benzingacom competitors name chg  market cap biomarin pharmaceutical inc  b celgene corp  b astrazeneca plc adr  b johnson  johnson  b eli lilly  co  b competitor data provided by partner content trending tickers powered by amzn  spy  sbux  uvxy  twtr  advanced search stocks columns authors topics no results found video center learn morestoryful a division of news corp which owns marketwatch is a leading social media services company headquartered in dublin ireland storyful combines world class journalism with industryleading technology to discover verify and acquire original content and provide the ontheground sources news and media organizations need to tell the stories that matter to their audience stocks index  markets index bulletin investor alert new york markets open in market snapshot analyst ratings stocks rates funds bonds benchmarks real estate investment trusts futures american depository receipt stocks exchange traded notes warrants indexes exchange traded funds currencies crypto currencies browse stocks stocks az abcdefghijklmnopqrstuvwxyzother browse by location argentina australia austria bahamas bahrain belgium bermuda botswana brazil british virgin islands canada cayman islands chile china colombia curacao cyprus czech republic denmark egypt estonia finland france germany gibraltar greece hong kong hungary iceland india indonesia ireland isle of man israel italy japan jordan kazakhstan kuwait latvia lebanon liechtenstein lithuania luxembourg malaysia malta mauritius mexico monaco money rates morocco namibia netherlands new zealand norway oman pakistan panama peru philippines poland portugal qatar romania russia saudi arabia singapore slovakia slovenia south africa south korea spain sri lanka sweden switzerland taiwan thailand tunisia turkey ukraine united arab emirates united states venezuela western samoa log in  am edt july   marketstatecountryus new york pre marketstatecountryuk london open marketstatecountryjp tokyo closed marketstatecountryus   marketstatecountryuk   marketstatecountryjp   view all latest news newslatest aset yourself up to get the most out of retirement aeuropean stocks sell off as ubs falls tech worries weigh aprince william and kate middleton are hiring— though not for these weird five royal family jobs arightmove profit rises on ad sales abank of ireland profit falls to restart dividend ahow do i get a reverse mortgage aus tech stocks shape up for another day of selling after amazon disappoints athis city’s subway system will soon run entirely on renewable energy a‘skinny’ repeal of obamacare fails to pass in latenight senate vote aubs credit suisse profit up after strategic shift arenault firsthalf profit leaps on higher volume aftse  under pressure as bt pushed lower afrances cac  falls  dropping further in early friday trade abarclays falls  after earnings report abritish airways parent iag rises  after quarterly profit report abritish airways parent iags profit soars agermanys dax opens  lower at  afrances cac  opens  lower at  alinde profit slides on restructuring costs auks ftse  opens  lower at  loading more headlines dow quoteszigmanrealtime    nasdaq quoteszigmanrealtime    sp  quoteszigmanrealtime    kiosk   the retirementors retirement advice from our industry experts our team of financial professionals can help you plan and save for retirement then live well in it congakioskretirementorshtml    alerts congakioskalertshtml    virtual stock exchange our free stockmarket game • trade your virtual portfolio in real time • talk strategies in group discussions • find or create a game that suits you • use our learning center to improve congakioskgameshtml    location scouts housingmarket insights from our realty pros plus the latest data from realtorcom on  home markets across the us • see our complete real estate site congakioskrealestatehtml    lazy portfolios set it and forget it check out the returns on our  lazy portfolios that are made up of lowcost buyandhold index funds • how to create your own lazy portfolio congakiosklazyportfoliohtml  marketwatchcom site index topics help feedback newsroom roster media archive premium products mobile company info code of conduct corrections advertising media kit advertise locally reprints  licensing broker center your ad choices follow marketwatch rss podcasts wsjcom barrons online bigcharts virtual stock exchange financial news london wsjcom small business realtorcom mansion global copyright   marketwatch inc all rights reserved by using this site you agree to the terms of service privacy policy and cookie policy intraday data provided by six financial information and subject to terms of use historical and current endofday data provided by six financial information all quotes are in local exchange time realtime last sale data for us stock quotes reflect trades reported through nasdaq only intraday data delayed at least  minutes or per exchange requirements marketwatch top stories link to marketwatchs slice  clvs stock price  clovis oncology inc stock quote us nasdaq  marketwatch sections watchlist signup • login search bulletin us europe asia fx rates futures range d d m m m y y dow    sp     nasdaq    globaldow    gold    oil    sp  movers adp  tsco  vz  orly  ca  jci  ffiv  xl  latest newsall times eastern a prince william and kate middleton are hiring— though not for these weird five royal family jobs a set yourself up to get the most out of retirement a updated european stocks sell off as ubs falls tech worries weigh a rightmove profit rises on ad sales a how do i get a reverse mortgage a bank of ireland profit falls to restart dividend a us tech stocks shape up for another day of selling after amazon disappoints a this city’s subway system will soon run entirely on renewable energy a ‘skinny’ repeal of obamacare fails to pass in latenight senate vote a ubs credit suisse profit up after strategic shift to be replaced home investing quotes stocks united states clvs overview compare quotes stock screener earnings calendar sectors nasdaq clvs us nasdaq join td ameritrade find a broker clovis oncology inc watchlist createclvsalert after hours last updated jul    pm edt delayed quote     after hours volume k close chg chg     advanced charting d d m m m ytd y y all   vol advanced charting  vs avg volume m  day avg  m open  close   day lowhigh  day range   week lowhigh  your watchlist customize marketwatch have watchlists log in to see them here or sign up to get started create account … or log in symbol last chg chg  no items in watchlist there are currently no items in this watchlist add ticker to watchlist go to your watchlist no saved watchlists create a list of the investments you want to track create watchlist …or try this starter list uh oh something went wrong while loading watchlist go to watchlist recently viewed tickers no recent tickers visit a quote page and your recently viewed tickers will be displayed here search tickers overview profile news charts financials historical quotes analyst estimates options sec filings insiders key data open  day range     week range    market cap b shares outstanding m public float m beta  rev per employee k pe ratio na eps  yield na dividend na exdividend date na short interest m   of float shorted  average volume m performance  day   month   month  ytd   year  recent news marketwatch other dow jones clovis oncology stock price target raised to  from  at jp morgan clovis oncology stock price target raised to  from  at jp morgan jun   at  am et by tomi kilgore clovis oncology to launch  mln stock offering clovis oncology inc said on monday it plans to launch a  million stock offering the announcement follows a  surge in clovis oncology shares after the company released positive latestage trial results for cancer drug rubraca the stock offering proceeds will be used for various general purposes including sales and marketing for rubraca clovis oncology itself will be offering all shares of the common stock company shares have surged  over the last three months compared with a  rise in the sp   jun   at  pm et by emma court clovis oncology to launch  mln stock offering clovis oncology to launch  mln stock offering jun   at  pm et by emma court clovis oncology stock surges  on positive latestage cancer trial results clovis oncology inc shares surged  in premarket trade monday after the company said its latestage trial for a cancer drug met its primary endpoint and a key secondary endpoint clovis said it plans to try for food and drug administration approval for the drug rucaparib within the next four months for second line and later maintenance treatment for women with platinumsensitive ovarian cancer who have responded to their most recent platinum therapy leerink analyst michael schmidt described the latest results as bull case plays out the outcome looks to be the bestcasescenario for clvs he said adding the results look particularly impressive when compared to previous competitor data including companies like tesaro and astrazeneca  which are also developing a class of cancer drugs called parp inhibitors if approved rubraca would have the broadest label of any parp inhibitor in ovarian cancer which we think should bode well for the commercial uptake of the drug schmidt said calling the company a prime takeout candidate in three subgroups of women with ovarian fallopian tube or primary peritoneal cancer patients on rucaparib had improved progressionfree survival the phase  trials primary endpoint progressionfree survival was also improved in patient on the drug as compared with placebo a key secondary endpoint clovis oncology said the trial enrolled  women clovis oncology shares have dropped  to  over the last three months compared with a  rise in the sp   jun   at  am et by emma court clovis oncologys stock soars  premarket after positive phase  trial results clovis oncologys stock soars  premarket after positive phase  trial results jun   at  am et by tomi kilgore clovis oncology stock price target raised to  from  at jp morgan clovis oncology stock price target raised to  from  at jp morgan may   at  am et by tomi kilgore clovis oncology upgraded to overweight from neutral at jp morgan clovis oncology upgraded to overweight from neutral at jp morgan may   at  am et by tomi kilgore tesaro stock dives  after drug pricing snafu apr   at  am et by emma court morgan stanley is bullish on gambling bearish on jelly apr   at  pm et by ryan vlastelica these corporate ties will be on display at scott gottlieb’s fda commissioner confirmation hearing today apr   at  am et by emma court tesaro won’t reveal price of its ovarian cancer drug but it’ll likely be near  a month mar   at  am et by emma court opinion  tech and biotech stocks with momentum mar   at  am et by harry boxer growthstock speculators need to tap the brakes here dec   at  pm et by kevin marder  stocks to watch dec   at  pm et by harry boxer clovis oncologys stock resumes trade up  at highest closing level since nov   dec   at  pm et by tomi kilgore clovis oncologys ovarian cancer treatment gets fda ok dec   at  am et by tomi kilgore clovis oncologys stock was up  prior to trading halt dec   at  am et by tomi kilgore clovis oncologys cancer treatment rubraca gets fda approval dec   at  am et by tomi kilgore clovis oncologys stock halted for news dec   at  am et by tomi kilgore in focus the sp is better but not there yet sep   at  am et by lawrence g mcmillan charting the market the financial magazine’s graphic look at selected stock activity for the week ended june   included are oracle amd and winnebago jun   at  am et on barrons online us stocks climb as tech sector bounces back us stocks finished higher driven by gains in technology shares with the dow industrials and sp  ending at new records jun   at  pm et on the wall street journal the dark side of good news in biotech deal making is a staple of the biotech industry but betting on mergers and acquisitions is much harder than it looks for investors jun   at  am et on the wall street journal stocks to watch apple amazon rice energy valeant among the companies with shares expected to trade actively in monday’s session are apple inc and other highflying tech stocks rice energy inc and valeant pharmaceuticals international inc jun   at  am et on the wall street journal tesaro explores sale tesaro is exploring a sale according to people familiar with the matter two months after the cancertreatment developer won a key drug approval may   at  pm et on the wall street journal biotech ma trade hits a snag mar   at  am et on the wall street journal resisting the allure of gilead mar   at  am et on barrons big pharma not small investors is driving biotech values now sep   at  pm et on the wall street journal would gilead pick up tesaro’s parp sep   at  pm et on barrons new drugs for ovarian cancer patients sep   at  am et on the wall street journal stocks to watch jp morgan bank of america delphi automotive pultegroup apr   at  am et on the wall street journal fda panel opposes approval of clovis lungcancer treatment apr   at  pm et on the wall street journal us stocks rally led by energy sector nov   at  pm et on the wall street journal astrazeneca’s lungcancer drug tagrisso gets fda’s approval nov   at  pm et on the wall street journal astrazeneca gets fda approval for ovarian cancer drug dec   at  pm et on the wall street journal top biotech picks for q earnings jul   at  am et on barrons stocks to watch staples tjx urban outfitters may   at  am et on the wall street journal stocks to watch citigroup gamestop winnebago mar   at  am et on the wall street journal intercept pharmaceuticals the mother of all momentum stocks jan   at  pm et on the wall street journal healthcare stocks where to find value nov   at  am et on barrons recent news other news press releases whats in the cards for aerie aeri this earnings season aerie pharmaceuticals aeri is expected to throw light on updates on rhopressa during its secondquarter earnings call on aug  jul   at  pm et on zackscom how astrazeneca failed not once — but twice — in cancer drugs astrazeneca azn not only failed in a lung cancer trial — which had the side effect of sending rival bristolmyers squibb bmy spiraling — but its partnership with dows merck mrk appears to be an admission of defeat in the initial immunooncology race shares of astrazeneca and bristolmyers sold off in droves early thursday on the stock market today astrazeneca took a pitfall to a fivemonth low down  near  bristol too jul   at  pm et on investors business daily astrazenecas lynparza deal with merck stokes fellow parp developer clovis shares ahead  astrazenecas lynparza deal with merck stokes fellow parp developer clovis shares ahead  jul   at  pm et on seeking alpha can biomarin bmrn keep the earnings streak alive in q biomarin pharmaceutical inc bmrn is likely to see continued momentum in vimizim and kuvan sales backed by robust patient growth in q jul   at  am et on zackscom whats in store for endocyte ecyt this earnings season endocyte ecyt looks forward to shift its focus on car tcell smallmolecule drug conjugates smdcs adaptor platform the dualtargeted dna crosslinker drug ec in q jul   at  am et on zackscom aveo pharmaceuticals aveo q earnings whats in store aveo pharmaceuticals aveo depends on collaboration revenues and milestone and other payments for its top line the chmp recommendation for tivozanib maa received during the quarter was a positive jul   at  am et on zackscom biotech bonanza the next leg up biotech bonanza the next leg up jul   at  pm et on seeking alpha hershey trust co buys eagle pharmaceuticals inc momo inc clovis oncology inc sells atlassian  hershey trust co buys eagle pharmaceuticals inc momo inc clovis oncology inc sells atlassian corporation plc ametek inc nimble storage inc jul   at  pm et on gurufocuscom whats in the cards for merck kgaa mkgaf in q earnings merck kgaas mkgaf life science segment is expected to perform well following the approval of bavencio jul   at  am et on zackscom  stocks at week highs still worth buying jul   at  am et on motley fool gilead could acquire this biotech — but vertex is still better analyst gilead sciences gild could fill a hole in its portfolio by acquiring incyte incy an analyst suggested friday offering one caveat — vertex pharmaceuticals vrtx would still be a less risky bet though gilead could make a play now for incyte — to the tune of a  premium on its stock price — the no  biotech would largely be betting on the commercial success of incytes immunooncology drug epacadostat meanwhile its dealing with a jul   at  pm et on investors business daily could q surprise spike this beleaguered biotechs stock a key hepatitis c drug from gilead sciences gild could top wall streets expectations but investors will be tuning into the companys secondquarter report on july  for more hints on potential ma activity an analyst said friday gileads hepatitis c sales slipped in  and in the months following the no  biotech said it could be open to a deal especially in oncology analysts have been quick to offer up incyte incy tesaro tsro jul   at  pm et on investors business daily clovis clvs focuses on rubraca launch and label expansion we issued an updated research report on boulder cobased clovis oncology inc clvs on jul  jul   at  pm et on zackscom heres why clovis oncology inc jumped  in june jul   at  am et on motley fool this rebounding pharma stock may launch another breakout move after breakouts from biotech stocks like celgene celg clovis oncology clvs and bioverativ bivv irelandbased ethical drugs firm jazz pharmaceuticals jazz is trying to return to its former wall street glory and launch another big run the developer of specialty drugs for narcolepsy oncology pain and psychiatry earned an upgrade to its relative strength rs rating friday from  to  over  years of market history reveals that the jun   at  pm et on investors business daily gilead and vertex should join — but dont hold your breath analyst gilead sciences gild would be better off acquiring vertex pharmaceuticals vrtx than an oncology asset like tesaro tsro or incyte incy an analyst suggested friday as he lamented gileads cautious approach to mergers the no  biotech by market cap has shown interest in making an oncologycentric buy as it struggles with declining hepatitis c drug sales the hepatitis c franchise brought in north of  billion over three years but fell jun   at  pm et on investors business daily  stocks that turned  into at least  in just one year jun   at  am et on motley fool is it too late to buy clovis oncology stock jun   at  pm et on motley fool will abbvie outsmart biosimilars and can clovis win the parp race jun   at  am et on motley fool is clovis oncology a takeover candidate is clovis oncology a takeover candidate jun   at  pm et on seeking alpha technical snapshots for these biotech stocks  exelixis celldex therapeutics clovis oncology and geron technical snapshots for these biotech stocks  exelixis celldex therapeutics clovis oncology and geron jul   at  am et on pr newswire  prf clovis oncology to announce second quarter  financial results and host webcast conference call on august  clovis oncology to announce second quarter  financial results and host webcast conference call on august  jul   at  am et on businesswire  bzx clovis oncology announces exercise in full of underwriters’ option to purchase additional shares of common stock clovis oncology announces exercise in full of underwriters’ option to purchase additional shares of common stock jun   at  pm et on businesswire  bzx biopharma stock breakouts with significant developments and market activity biopharma stock breakouts with significant developments and market activity jun   at  pm et on pr newswire  prf key pharma stocks with advanced developments and breakthrough discoveries key pharma stocks with advanced developments and breakthrough discoveries jun   at  am et on pr newswire  prf clovis oncology announces upsizing and pricing of public offering of common stock clovis oncology announces upsizing and pricing of public offering of common stock jun   at  pm et on businesswire  bzx todays research reports on stocks to watch clovis oncology and valeant pharmaceuticals todays research reports on stocks to watch clovis oncology and valeant pharmaceuticals jun   at  am et on accesswire clovis oncology announces proposed offering of common stock clovis oncology announces proposed offering of common stock jun   at  pm et on businesswire  bzx sienna biopharmaceuticals appoints erle mast former cfo and cofounder of clovis oncology to board of directors sienna biopharmaceuticals appoints erle mast former cfo and cofounder of clovis oncology to board of directors jun   at  am et on globenewswire clovis oncology announces presentations at  asco annual meeting clovis oncology announces presentations at  asco annual meeting may   at  am et on businesswire  bzx investor network clovis oncology inc to host earnings call investor network clovis oncology inc to host earnings call may   at  am et on accesswire myriad genetics and clovis oncology sign agreement for use of fdaapproved bracanalysis cdxr test to identify patients with germline brca mutations for rubracar rucaparib treatment apr   at  am et on globenewswire clovis oncology to announce first quarter  financial results and host webcast conference call on may  apr   at  am et on businesswire  bzx todays research reports on biotech stocks to watch nektar therapeutics and clovis oncology apr   at  am et on accesswire research reports initiation on biotech stocks  sarepta therapeutics galena biopharma anthera pharma and clovis oncology apr   at  am et on pr newswire  prf global oncology market gains ground driven by innovative cancer treatment therapies apr   at  am et on pr newswire  prf pancreatic cancer treatment market analysis by affected region exocrine endocrine by type chemotherapy targeted therapy others by region north america europe asia pacific latin america and mea and segment forecasts    mar   at  pm et on pr newswire  prf shareholder alert law office of brodsky  smith llc announces investigation of the board of directors of clovis oncology inc  clvs mar   at  pm et on accesswire  biotech companies set for major breakouts in  mar   at  am et on pr newswire  prf biotech stocks under scanner  acadia pharma clovis oncology galena biopharma and northwest biotherapeutics feb   at  am et on pr newswire  prf clovis oncology inc clovis oncology inc is a biopharmaceutical company which focuses on acquiring developing and commercializing cancer treatments in the united states europe and other international markets the company has three product candidates in its clinical development pipeline rociletinib rucaparib and lucitani clovis oncology was founded by andrew r allen gillian c iversread patrick j mahaffy and erle t mast on april   and is headquartered in boulder co see full profile analyst ratings sell under hold over buy number of ratings  full ratings what to expect from clovis oncology following rubraca approval jun   at  pm et on benzingacom benzingas top upgrades downgrades for june   jun   at  am et on benzingacom clovis addresses some of the companys biggest controversies jun   at  pm et on benzingacom competitors name chg  market cap biomarin pharmaceutical inc  b celgene corp  b astrazeneca plc adr  b johnson  johnson  b eli lilly  co  b competitor data provided by partner content trending tickers powered by amzn  spy  sbux  uvxy  twtr  advanced search stocks columns authors topics no results found video center learn morestoryful a division of news corp which owns marketwatch is a leading social media services company headquartered in dublin ireland storyful combines world class journalism with industryleading technology to discover verify and acquire original content and provide the ontheground sources news and media organizations need to tell the stories that matter to their audience clovis oncology inc  product pipeline review    reportsnreports market research report welcome guest    registerlogin   contact us   about us      advanced search home ›  pharmaceuticals ›  report detail clovis oncology inc  product pipeline review   published april  no of pages  price  single user license us   corporate user license us     report description table of contents inquire before buying global markets directs clovis oncology inc product pipeline review  provides an overview of the clovis oncology incs pharmaceutical research and development focusthis report provides comprehensive information on the current therapeutic developmental pipeline of clovis oncology incs complete with comparative analysis at various stages therapeutics assessment by drug target mechanism of action moa route of administration roa and molecule type it also reviews latest updates and featured news and press releases along with special features on latestage and discontinued projectsglobal markets directs report features investigational drugs from across globe covering over  therapy areas and nearly  indications the report is built using data and information sourced from global markets directs proprietary databases companyuniversity websites sec filings investor presentations and featured press releases from companyuniversity sites and industryspecific third party sources put together by global markets directs team drug profilesrecords featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information additionally processes including live news  deals tracking browser based alertbox and clinical trials registries tracking ensure that the most recent developments are captured on a real time basisthe report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage it strengthens rd pipelines by identifying new targets and moas to produce firstinclass and bestinclass productsnote certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated diseasescopethe report provides brief overview of clovis oncology inc including business description key information and facts and its locations and subsidiariesthe report reviews current pipeline of clovis oncology incs human therapeutic division and enlists all their major and minor projectsthe report features product description and descriptive mechanism of action for key pipeline products along with the products developmental history and major milestonesspecial feature on outlicensed and partnered product portfoliothe report summarizes all the dormant and discontinued pipeline projectslatest company statementlatest news and deals relating to the clovis oncology incs pipeline productsreasons to buyevaluate clovis oncology incs strategic position with total access to detailed information on its product pipelineassess the growth potential of clovis oncology inc in its therapy areas of focusidentify new drug targets and therapeutic classes in the clovis oncology incs rd portfolio and develop key strategic initiatives to reinforce pipeline in those areasexploit inlicensing opportunities by identifying windows of opportunity to fill portfolio gapsdevelop strategic initiatives by understanding the focus areas of clovis oncology inc and exploit collaboration and partnership opportunitiesidentify emerging players with potentially strong product portfolio and create effective counterstrategies to gain competitive advantageplan mergers and acquisitions effectively by identifying the most promising pipeline of clovis oncology incdevelop and design inlicensing and outlicensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scopeexplore the dormant and discontinued projects of clovis oncology inc and identify potential opportunities in those areasavoid intellectual property rights related issues clovis oncology inc  product pipeline review   table of contentstable of contents list of tables list of figures clovis oncology inc snapshot clovis oncology inc overview key information key facts clovis oncology inc  research and development overview key therapeutic areas clovis oncology inc  pipeline review pipeline products by stage of development pipeline products  monotherapy pipeline products  partnered products partnered productscombination treatment modalities clovis oncology inc  pipeline products glance clovis oncology inc  late stage pipeline products phase iii productscombination treatment modalities clovis oncology inc  clinical stage pipeline products phase ii productscombination treatment modalities phase i productscombination treatment modalities clovis oncology inc  early stage pipeline products discovery productscombination treatment modalities clovis oncology inc  drug profiles rucaparib phosphate product description mechanism of action rd progress co product description mechanism of action rd progress lucitanib product description mechanism of action rd progress mutant ckit inhibitor product description mechanism of action rd progress clovis oncology inc  pipeline analysis clovis oncology inc  pipeline products by target clovis oncology inc  pipeline products by route of administration clovis oncology inc  pipeline products by molecule type clovis oncology inc  pipeline products by mechanism of action clovis oncology inc  recent pipeline updates clovis oncology inc  company statement clovis oncology inc  locations and subsidiaries head office other locations  subsidiaries appendix methodology coverage secondary research primary research expert panel validation contact us disclaimer list of tablesclovis oncology inc key information clovis oncology inc key facts clovis oncology inc  pipeline by indication  clovis oncology inc  pipeline by stage of development  clovis oncology inc  monotherapy products in pipeline  clovis oncology inc  partnered products in pipeline  clovis oncology inc  partnered products combination treatment modalities  clovis oncology inc  phase iii  clovis oncology inc  phase ii  clovis oncology inc  phase i  clovis oncology inc  discovery  clovis oncology inc  pipeline by target  clovis oncology inc  pipeline by route of administration  clovis oncology inc  pipeline by molecule type  clovis oncology inc  pipeline products by mechanism of action  clovis oncology inc  recent pipeline updates  clovis oncology inc other locations clovis oncology inc subsidiaries list of figuresclovis oncology inc  pipeline by top  indication  clovis oncology inc  pipeline by stage of development  clovis oncology inc  monotherapy products in pipeline  clovis oncology inc  partnered products in pipeline  clovis oncology inc  pipeline by top  target  clovis oncology inc  pipeline by top  route of administration  clovis oncology inc  pipeline by top  molecule type  clovis oncology inc  pipeline products by top  mechanism of action   published by global markets direct product code global markets direct did you find what you arewere looking for  if not read below and browse through other relevant pages for similar market research reports or get in touch with us through the formcontact info in your right navigation panel and well share relevant market report titles for you to explore related reports global ion channel modulators market research report  in this report the global ion channel modulators market is valued at usd xx million in  and is expected to reach usd xx million by the end of  growing at a cagr of xx between  and  geographically this report is segmented into  global albumin market research report  in this report the global albumin market is valued at usd xx million in  and is expected to reach usd xx million by the end of  growing at a cagr of xx between  and  geographically this report is segmented into several key reg global vaginitis therapeutics market research report  in this report the global vaginitis therapeutics market is valued at usd xx million in  and is expected to reach usd xx million by the end of  growing at a cagr of xx between  and  geographically this report is segmented into  global urinary tract infection therapeutics market research report  in this report the global urinary tract infection therapeutics market is valued at usd xx million in  and is expected to reach usd xx million by the end of  growing at a cagr of xx between  and  geographically this report is s global bone anchored hearing aids market research report  in this report the global bone anchored hearing aids market is valued at usd xx million in  and is expected to reach usd xx million by the end of  growing at a cagr of xx between  and  geographically this report is segmented i global porcine vaccine market research report  in this report the global porcine vaccine market is valued at usd xx million in  and is expected to reach usd xx million by the end of  growing at a cagr of xx between  and  geographically this report is segmented into several global pharmaceutical market by manufacturers countries type and application forecast to  the pharmaceutical industry discovers develops produces and markets drugs or pharmaceutical drugs for use as medications pharmaceutical companies may deal in generic or brand medications scope of the report this report focuses on the pharma  united states physiological saline market report status and outlook this report will be delivered in  business days after the order is placed the physiological saline market size will be xx million usd in  in united states from the xx million usd in  with a cagr compound annual growth rate xx  philippines physiological saline market report status and outlook this report will be delivered in  business days after the order is placed the physiological saline market size will be xx million usd in  in philippines from the xx million usd in  with a cagr compound annual growth rate xx   malaysia physiological saline market report status and outlook this report will be delivered in  business days after the order is placed the physiological saline market size will be xx million usd in  in malaysia from the xx million usd in  with a cagr compound annual growth rate xx fro why reportsnreportscom  market research reports and growing top fortune  organizations trust us for research data  support on call as well as emails your details are safe with us free support for your research requirements report delivery email delivery time upto  hrs  working days upto  hrs max  weekends and public holidays research support  custom research if this business study does not have the data and information analysis you need contact us with your research requirements we explore available market research reports to map your needs and share report titles with you alternatively we can also offer custom research that suits your budget and timelines share your information requirements here connect with us email salesreportsandreportscom call       home category publisher country latest reports markets discounted reports upcoming reports contact us subscription option using our subscription option you get access to market research reports and industry data of consumer goods market as per your needs get the best of consumer goods research reports by utilizing your research budgets in an optimum way more about our subscription option report alerts get email alerts about market research reports from industries and publishers of your interest please enter a valid email id thank you you have successfully subscribed to our report alerts avail upto  discount on below publisher reports technavio azoth analytics   reportsnreports all rights reserved disclamer privacy policy  terms and conditions  our market research blog  sitemap feeds rss  latest reports clovis oncology inc  product pipeline review    compare about us  contact us home research category publisher list custom research cart compare research category user guide policies contact us about us site map home  market research report  pharmaceutical  pharmaceutical companies  pharma info market research report clovis oncology inc  product pipeline review   published by global markets direct product code  published april   content info  pages price usd  pdf by email single user license usd  pdf by email site license usd  pdf by email global license clovis oncology inc  product pipeline review   published april   content info  pages description global markets directs clovis oncology inc  product pipeline review   provides an overview of the clovis oncology incs pharmaceutical research and development focus this report provides comprehensive information on the current therapeutic developmental pipeline of clovis oncology incs complete with comparative analysis at various stages therapeutics assessment by drug target mechanism of action moa route of administration roa and molecule type it also reviews latest updates and featured news and press releases along with special features on latestage and discontinued projects global markets directs report features investigational drugs from across globe covering over  therapy areas and nearly  indications the report is built using data and information sourced from global markets directs proprietary databases companyuniversity websites sec filings investor presentations and featured press releases from companyuniversity sites and industryspecific third party sources put together by global markets directs team drug profilesrecords featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information additionally processes including live news  deals tracking browser based alertbox and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis the report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage it strengthens rd pipelines by identifying new targets and moas to produce firstinclass and bestinclass products note certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease scope the report provides brief overview of clovis oncology inc including business description key information and facts and its locations and subsidiaries the report reviews current pipeline of clovis oncology incs human therapeutic division and enlists all their major and minor projects the report features product description and descriptive mechanism of action for key pipeline products along with the products developmental history and major milestones special feature on outlicensed and partnered product portfolio the report summarizes all the dormant and discontinued pipeline projects latest company statement latest news and deals relating to the clovis oncology incs pipeline products reasons to buy evaluate clovis oncology incs strategic position with total access to detailed information on its product pipeline assess the growth potential of clovis oncology inc in its therapy areas of focus identify new drug targets and therapeutic classes in the clovis oncology incs rd portfolio and develop key strategic initiatives to reinforce pipeline in those areas exploit inlicensing opportunities by identifying windows of opportunity to fill portfolio gaps develop strategic initiatives by understanding the focus areas of clovis oncology inc and exploit collaboration and partnership opportunities identify emerging players with potentially strong product portfolio and create effective counterstrategies to gain competitive advantage plan mergers and acquisitions effectively by identifying the most promising pipeline of clovis oncology inc develop and design inlicensing and outlicensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope explore the dormant and discontinued projects of clovis oncology inc and identify potential opportunities in those areas avoid intellectual property rights related issues table of contents product code gmdhccdb table of contents table of contents list of tables list of figures clovis oncology inc snapshot clovis oncology inc overview key information key facts clovis oncology inc  research and development overview key therapeutic areas clovis oncology inc  pipeline review pipeline products by stage of development pipeline products  monotherapy pipeline products  partnered products partnered productscombination treatment modalities clovis oncology inc  pipeline products glance clovis oncology inc  late stage pipeline products phase iii productscombination treatment modalities clovis oncology inc  clinical stage pipeline products phase ii productscombination treatment modalities phase i productscombination treatment modalities clovis oncology inc  early stage pipeline products discovery productscombination treatment modalities clovis oncology inc  drug profiles rucaparib phosphate product description mechanism of action rd progress co product description mechanism of action rd progress lucitanib product description mechanism of action rd progress mutant ckit inhibitor product description mechanism of action rd progress clovis oncology inc  pipeline analysis clovis oncology inc  pipeline products by target clovis oncology inc  pipeline products by route of administration clovis oncology inc  pipeline products by molecule type clovis oncology inc  pipeline products by mechanism of action clovis oncology inc  recent pipeline updates clovis oncology inc  company statement clovis oncology inc  locations and subsidiaries head office other locations  subsidiaries appendix methodology coverage secondary research primary research expert panel validation contact us disclaimer list of tables clovis oncology inc key information clovis oncology inc key facts clovis oncology inc  pipeline by indication  clovis oncology inc  pipeline by stage of development  clovis oncology inc  monotherapy products in pipeline  clovis oncology inc  partnered products in pipeline  clovis oncology inc  partnered products combination treatment modalities  clovis oncology inc  phase iii  clovis oncology inc  phase ii  clovis oncology inc  phase i  clovis oncology inc  discovery  clovis oncology inc  pipeline by target  clovis oncology inc  pipeline by route of administration  clovis oncology inc  pipeline by molecule type  clovis oncology inc  pipeline products by mechanism of action  clovis oncology inc  recent pipeline updates  clovis oncology inc other locations clovis oncology inc subsidiaries list of figures clovis oncology inc  pipeline by top  indication  clovis oncology inc  pipeline by stage of development  clovis oncology inc  monotherapy products in pipeline  clovis oncology inc  partnered products in pipeline  clovis oncology inc  pipeline by top  target  clovis oncology inc  pipeline by top  route of administration  clovis oncology inc  pipeline by top  molecule type  clovis oncology inc  pipeline products by top  mechanism of action  phone intl  tollfreeus  europe  asia  new for   gii now purchases any market research reports from any publishers for you with noextra cost contact us for more details faq delivery time user license payment options compare multiple reports about contact user guide policies site map  copyright  global information inc all rights reserved stockscountryunited states index  markets index bulletin investor alert new york markets open in market snapshot analyst ratings stocks rates funds bonds benchmarks real estate investment trusts futures american depository receipt stocks exchange traded notes warrants indexes exchange traded funds currencies crypto currencies location united states name exchange sector  communique laboratory inc ocqlf ootc software  property insurance holdings inc pih xnas nonlife insurance flowerscom inc cl a flws xnas specialty retail pm industries inc opmz ootc food products st capital bank ca fisb ootc banking st constitution bancorp fccy xnas banking st nrg corp fnrc ootc oil extraction st source corp srce xnas banking  motors inc etfm ootc automobiles st century fox inc cl a foxa xnas broadcasting st century fox inc cl b fox xnas broadcasting vianet group inc adr vnet xnas internetonline nd century group inc xxii xase biotechnology  kid doc inc tvmd ootc healthcare provision u inc twou xnas software xleveraged long etracs linked to wells fargo business development co index  bdcl arcx major international banks xleveraged long etracs wells fargo business development lbdc arcx major international banks d eye solutions inc tdey ootc motion picturesound recording d pioneer systems inc dpsm ootc software d systems corp ddd xnys computersconsumer electronics dicon corp tdcp ootc software dshoppingcom thds ootc mixed retailing dx industries inc dddx ootc computersconsumer electronics i group plc adr tgopy ootc finance companies m co mmm xnys diversified holding companies pea international inc tpnl xotc accounting power energy group inc pspw ootc renewable energy generation tl technologies corp ttmzf ootc advertisingmarketingpublic relations  property management inc ftpm ootc real estate agentsbrokers cable tv international inc catv ootc diversified business services licensing corp fourq ootc diversified business services com ltd adr wbai xnys gambling industries job inc adr jobs xnas employmenttraining services com inc adr wuba xnys consumer services barz international inc barz ootc networking n plus inc fplsf ootc commodity chemicals d global technologies inc sixd ootc computer services  renewable energy corp rnwr ootc multiutilities  energy ltd adr tngry ootc oil extraction  holdings plc eihdf ootc gambling industries point energy partners lp cafd xnas renewable energy generation x inc eght xnas wired telecommunications services a clean slate inc drwn ootc diversified business services aw revenue royalties income fund awrrf ootc restaurants a h belo corp series a ahc xnys publishing a schulman inc shlm xnas commodity chemicals a schulman inc  pfd slmnp ootc commodity chemicals ad makepeace co make ootc farming am castle  co cas xnys wholesalers ao smith corp aos xnys building materialsproducts ap moellermaersk as adr amkby ootc water transportshipping ap moellermaersk as series a amkaf ootc water transportshipping ap moellermaersk as series b amkbf ootc water transportshipping as roma spa asraf ootc recreational services a group inc awon ootc tobacco a networks inc aten xnys computer services a milk co ltd acopf ootc biotechnology aac holdings inc aac xnys healthcare provision aac technologies holdings inc aacaf ootc industrial electronics aac technologies holdings inc adr aacay ootc industrial electronics aaon inc aaon xnas building materialsproducts aap inc aapj ootc food products aar corp air xnys aerospace productsparts aarons inc aan xnys consumer services ab science sa abscf ootc pharmaceuticals ab svensk exportkredit elements linked to mlcx biofuels index total return fue arcx finance companies ab svensk exportkredit elements linked to mlcx grain index total return gru arcx finance companies abt financial corp abto ootc banking abacus mining  exploration corp abcff ootc general mining abakan inc abki ootc industrial products abattis bioceuticals corp attbf ootc biotechnology abaxis inc abax xnas medical equipmentsupplies abb ltd ablzf ootc industrial machinery abb ltd adr abb xnys industrial machinery abbott laboratories abt xnys pharmaceuticals abbvie inc abbv xnys biotechnology abby inc abby ootc oil extraction abcam plc abczf ootc biotechnology abcam plc adr abczy ootc biotechnology abco energy inc abce ootc industrial machinery abcourt mines inc abmbf ootc general mining aben resources ltd abnaf ootc general mining abengoa sa b agoaf ootc construction abeona therapeutics inc abeo xnas biotechnology abeona therapeutics inc wt abeow xnas abercrombie  fitch co anf xnys clothing retail aberdeen asiapacific income fund inc fax xase closedend funds aberdeen asiapacific income investment co ltd abakf ootc closedend funds aberdeen asset management plc abdnf ootc investment advisors aberdeen asset management plc adr abdny ootc investment advisors aberdeen australia equity fund inc iaf xase closedend funds aberdeen chile fund inc ch xase closedend funds aberdeen emerging markets smaller company opportunities fund inc abe xase closedend funds aberdeen global income fund inc fco xase closedend funds aberdeen greater china fund inc gch xnys closedend funds aberdeen indonesia fund inc if xase closedend funds aberdeen international inc aabvf ootc general mining aberdeen israel fund inc isl xase closedend funds aberdeen japan equity fund inc jeq xnys closedend funds aberdeen latin america equity fund inc laq xase closedend funds aberdeen singapore fund inc sgf xnys closedend funds abertis infraestructuras sa adr abrty ootc transportation services ability inc abil xnas precision products ability inc wt abiwf ootc abiomed inc abmd xnas medical equipmentsupplies abitibi royalties inc atbyf ootc general mining able energy inc able ootc gas utilities ablynx nv ablyf ootc biotechnology abm industries inc abm xnys diversified business services abraxas petroleum corp axas xnas oil extraction absecon bancorp ascn ootc banking absolute health  fitness inc ahfi ootc recreational services absolute software corp alswf ootc software abt holdings inc abot ootc precious metals abtech holdings inc abhd ootc industrial machinery abv consulting inc abvn ootc advertisingmarketingpublic relations ac immune sa aciu xnas biotechnology acacia communications inc acia xnas networking acacia diversified holdings inc acca ootc specialty retail acacia mining plc abglf ootc gold acacia research corp  acacia technologies actg xnas diversified business services acadia healthcare co inc achc xnas healthcare provision acadia pharmaceuticals inc acad xnas biotechnology acadia realty trust akr xnys acadian timber corp acazf ootc forestry  wood products acasti pharma inc acst xnas pharmaceuticals accelera innovations inc acnv ootc healthcare provision accelerate diagnostics inc axdx xnas biotechnology accelerize inc aclz xotc life insurance acceleron pharma inc xlrn xnas biotechnology accenture plc cl a acn xnys diversified business services access national corp ancx xnas banking access power inc accr ootc wired telecommunications services access worldwide communications inc awwc ootc advertisingmarketingpublic relations acciona sa acxif ootc construction acco brands corp acco xnys nondurable household products accor sa acrff ootc hotels accor sa adr accyy ootc hotels accordia golf co ltd acgff ootc recreational services accredited mortgage loan reit trust  perp cum pfd series a ahhap ootc mortgages accretive health inc achi ootc healthcare provision accuray inc aray xnas medical equipmentsupplies accuride corp acw xnys auto  commercial vehicle parts acelrx pharmaceuticals inc acrx xnas pharmaceuticals acer inc gdr reg s aceyy ootc computersconsumer electronics acerus pharmaceuticals corp trlpf ootc biotechnology aceto corp acet xnas specialty chemicals achaogen inc akao xnas biotechnology achillion pharmaceuticals inc achn xnas biotechnology aci worldwide inc aciw xnas software «» log in  am edt july   marketstatecountryus new york pre marketstatecountryuk london open marketstatecountryjp tokyo closed marketstatecountryus   marketstatecountryuk   marketstatecountryjp   view all latest news newslatest aset yourself up to get the most out of retirement aeuropean stocks sell off as ubs falls tech worries weigh aprince william and kate middleton are hiring— though not for these weird five royal family jobs arightmove profit rises on ad sales abank of ireland profit falls to restart dividend ahow do i get a reverse mortgage aus tech stocks shape up for another day of selling after amazon disappoints athis city’s subway system will soon run entirely on renewable energy a‘skinny’ repeal of obamacare fails to pass in latenight senate vote aubs credit suisse profit up after strategic shift arenault firsthalf profit leaps on higher volume aftse  under pressure as bt pushed lower afrances cac  falls  dropping further in early friday trade abarclays falls  after earnings report abritish airways parent iag rises  after quarterly profit report abritish airways parent iags profit soars agermanys dax opens  lower at  afrances cac  opens  lower at  alinde profit slides on restructuring costs auks ftse  opens  lower at  loading more headlines dow quoteszigmanrealtime    nasdaq quoteszigmanrealtime    sp  quoteszigmanrealtime    kiosk   the retirementors retirement advice from our industry experts our team of financial professionals can help you plan and save for retirement then live well in it congakioskretirementorshtml    alerts congakioskalertshtml    virtual stock exchange our free stockmarket game • trade your virtual portfolio in real time • talk strategies in group discussions • find or create a game that suits you • use our learning center to improve congakioskgameshtml    location scouts housingmarket insights from our realty pros plus the latest data from realtorcom on  home markets across the us • see our complete real estate site congakioskrealestatehtml    lazy portfolios set it and forget it check out the returns on our  lazy portfolios that are made up of lowcost buyandhold index funds • how to create your own lazy portfolio congakiosklazyportfoliohtml  marketwatchcom site index topics help feedback newsroom roster media archive premium products mobile company info code of conduct corrections advertising media kit advertise locally reprints  licensing broker center your ad choices follow marketwatch rss podcasts wsjcom barrons online bigcharts virtual stock exchange financial news london wsjcom small business realtorcom mansion global copyright   marketwatch inc all rights reserved by using this site you agree to the terms of service privacy policy and cookie policy intraday data provided by six financial information and subject to terms of use historical and current endofday data provided by six financial information all quotes are in local exchange time realtime last sale data for us stock quotes reflect trades reported through nasdaq only intraday data delayed at least  minutes or per exchange requirements marketwatch top stories link to marketwatchs slice  bing places for business bing places for business sign in using your microsoft account work account google account facebook account dont have an account create one clovis oncology  investors  news  investor faqhomeabout clovisleadershipproductspipelinepatients  caregiversbusiness developmentinvestors  news overview corporate governance sec filings stock information news releases webcasts  presentations annual meeting materials event calendar information request investor faqgrants  researchcareerscontactprintemailrss feedsemail alertsir contactsfinancial tear sheetinvestor faqwhat is the stock symbol and cusip number for clovis oncology common stockon what stock exchange is clovis oncology listedwhat year and where was clovis oncology incorporatedwho are clovis oncology’s independent auditorsdoes clovis oncology pay a dividend on common stockwho is clovis oncology’s transfer agentcan i purchase stock directly from the companywhat is the stock symbol and cusip number for clovis oncology common stock the stock symbol for clovis oncology common stock is clvs and the cusip number is  on what stock exchange is clovis oncology listed clovis oncology common stock is traded on the nasdaq global select marketwhat year and where was clovis oncology incorporated clovis oncology was incorporated in delaware in april who are clovis oncology’s independent auditors clovis oncology’s independent auditors are ernst  youngdoes clovis oncology pay a dividend on common stock clovis oncology has not paid a dividend to datewho is clovis oncology’s transfer agent continental stock transfer  trust company is our transfer agent their contact information follows continental stock transfer  trust company  battery place th floor new york ny  phone  fax can i purchase stock directly from the company no clovis oncology does not have a direct stock purchase plan share may be purchased through a financial services provider of your choice copyright   clovis oncology all rights reserved contact  terms of use  privacy policy  sitemap microsoft personalized ad preferences to opt out of personalized ads in this browser your browser history must allow firstparty and thirdparty cookies and you must have your browsing experience set to not delete browsing history on exit instructions for enabling cookies and configuring your browsing history may be available in your browsers settings privacy or help documentation sign in hold on… we’re sorry but this didn’t work you can’t turn off personalized ads right now because your browser is currently blocking thirdparty cookies we can help you fix this issue let’s get started depending on what browser you use open options or settings make sure that thirdparty cookies are not blocked anymore to find out how search your browser’s help revisit httpchoicemicrosoftcomoptout and then on the “personalized ads in this browser” tile click off ext about our ads to create a more customized online experience some of the ads you may receive on microsoft websites and apps are tailored to your previous activities searches and site visits youre in control and heres where you can make the advertising choice thats right for you ext where can i learn more about advertising on microsoft websites and apps microsoft partners with oath appnexus and other third party service providers to help present customized content and display advertisements on msn outlookcom and other websites and apps microsoft also delivers search ads to bing and our search syndication partners learn more about microsoft’s privacy practices here you can learn more about interestbased ads from oath and appnexus in their privacy statements oath and appnexus what choices do i have about interestbased advertising on this page you can opt out of receiving interest based advertising from microsoft you can also opt out of receiving interestbased advertising from all selfregulatory members including microsoft oath appnexus and other third party ad networks at the following sites in the us digital advertising alliance daa in europe european interactive digital advertising alliance edaa in canada ad choices digital advertising alliance of canada daac you can control interestbased advertising in windows apps by turning off the advertising id in windows settings more choices do you want personalized ads from other companies questions if you have a privacy question or a question for the chief privacy officer of microsoft please contact us by using our web form we will respond to questions within  days ext personalized ads in this browser off optout is currently unavailable please try again later control the personalized ads setting for this web browser learn more if you want microsoft to show ads that might be relevant to you click on to show “generic” ads click off ext personalized ads wherever i use my microsoft account off sign in to change optout is currently unavailable please try again later control the personalized ads setting that applies when you are signed in on any computer or device with your microsoft account including windows windows phone xbox and other devices learn more if you want microsoft to show ads that might be relevant to you click on to show “generic” ads click off if you choose “generic” ads and use a browser your choice applies to everyone when using that browser as long as you do not clear your cookies ext personalized ads in windows in your windows settings you can turn off personalized ads that appear in apps on this device you’ll still see ads but they won’t be personalized anymore if you have windows  access the charms by touching or moving your pointer to the right edge of the screen click or tap settings and then click or tap change pc settings click or tap privacy and then turn off let apps use my advertising id for experiences across apps if you have windows  click or tap the start button click or tap settings click or tap privacy and then turn off let apps use my advertising id for experiences across apps if you have a windows mobile device go to settings tap on privacy tap on advertising id and then turn off let apps use my advertising id for experiences across apps if you want to turn off personalized ads from microsoft wherever you use your microsoft account including apps on windows windows phone xbox and other devices you can do so by selecting the microsoft account option above ext legal privacy  cookies   microsoft clvs key statistics  clovis oncology inc financial ratios  marketwatch bulletin investor alert new york markets open in market snapshot analyst ratings expand keep open close expand keep open close expand keep open close expand keep open close expand keep open close clovis oncology inc nasdaq clvs go set alerts find a broker join td ameritrade market index overview profile news charts financials historical quotes analyst estimates options sec filings insiders marketstatecountryus clovis oncology inc after hours  quotes are delayed by  min jul    pm clvs quoteszigmancomposite   change   volume volume  quotes are delayed by  min quoteszigmancomposite previous close     change   day low day high    week low  week high   company description clovis oncology inc is a biopharmaceutical company which focuses on acquiring developing and commercializing cancer treatments in the united states europe and other international markets the company has three product candidates in its clinical development pipeline rociletinib rucaparib and lu clovis oncology inc is a biopharmaceutical company which focuses on acquiring developing and commercializing cancer treatments in the united states europe and other international markets the company has three product candidates in its clinical development pipeline rociletinib rucaparib and lucitani clovis oncology was founded by andrew r allen gillian c iversread patrick j mahaffy and erle t mast on april   and is headquartered in boulder co valuation pe current  pe ratio with extraordinary items  price to sales ratio  enterprise value to ebitda  enterprise value to sales  total debt to enterprise value  efficiency revenueemployee  income per employee  receivables turnover  total asset turnover  liquidity current ratio  quick ratio  cash ratio  profitability gross margin  operating margin  pretax margin  net margin  return on assets  return on equity  return on total capital  return on invested capital  capital structure total debt to total capital  total debt to total assets  longterm debt to total capital  officers and executives name age officer since title mr patrick j mahaffy   president chief executive officer  director mr daniel w muehl   svpfinance chief financial  accounting officer dr lindsey rolfe   chief medical officer  executive vpclinical ms gillian c iversread   chief regulatory officer  executive vp mr corwin dale hooks   chief commercial officer  senior vice president insider actions – purchase – sale  – number of transactions  date name shares transaction value  gillian c iversread see remarks    disposition at  per share   brian g atwood director      brian g atwood director      domain associates llc director      domain associates llc director      gillian c iversread see remarks    disposition at  per share   gillian c iversread see remarks    disposition at  per share   gillian c iversread see remarks    disposition at  per share   gillian c iversread see remarks    disposition at  per share   daniel w muehl see remarks    derivativenonderivative trans at  per share   daniel w muehl see remarks    derivativenonderivative trans at  per share   michael james barrett director      michael james barrett director      michael james barrett director      michael james barrett director      erle t mast executive vp and cfo    disposition at  per share   erle t mast executive vp and cfo    disposition at  per share   erle t mast executive vp and cfo    disposition at  per share   erle t mast executive vp and cfo    disposition at  per share   erle t mast executive vp and cfo    disposition at  per share   erle t mast executive vp and cfo    disposition at  per share   erle t mast executive vp and cfo    disposition at  per share   erle t mast executive vp and cfo    disposition at  per share  newslatestcompanyusclvs marketwatch news on clvs clovis oncology stock price target raised to  from  at jp morgan  am june    tomi kilgore clovis oncology to launch  mln stock offering  pm june    emma court clovis oncology to launch  mln stock offering  pm june    emma court clovis oncology stock surges  on positive latestage cancer trial results  am june    emma court clovis oncologys stock soars  premarket after positive phase  trial results  am june    tomi kilgore clovis oncology stock price target raised to  from  at jp morgan  am may    tomi kilgore clovis oncology upgraded to overweight from neutral at jp morgan  am may    tomi kilgore tesaro stock dives  after drug pricing snafu  am april    emma court morgan stanley is bullish on gambling bearish on jelly  pm april    ryan vlastelica these corporate ties will be on display at scott gottlieb’s fda commissioner confirmation hearing today  am april    emma court tesaro won’t reveal price of its ovarian cancer drug but it’ll likely be near  a month  am march    emma court  tech and biotech stocks with momentum  am march    harry boxer growthstock speculators need to tap the brakes here  pm dec    the trading deck  stocks to watch  pm dec    the trading deck clovis oncologys stock resumes trade up  at highest closing level since nov    pm dec    tomi kilgore clovis oncologys ovarian cancer treatment gets fda ok  pm dec    tomi kilgore clovis oncologys stock was up  prior to trading halt  pm dec    tomi kilgore clovis oncologys cancer treatment rubraca gets fda approval  pm dec    tomi kilgore clovis oncologys stock halted for news  pm dec    tomi kilgore in focus the sp is better but not there yet  am sept    lawrence g mcmillan loading more headlines newsnonmarketwatchcompanyusclvs other news on clvs whats in the cards for aerie aeri this earnings season  pm july    zackscom astrazenecas lynparza deal with merck stokes fellow parp developer clovis shares ahead   pm july    seeking alpha how astrazeneca failed not once — but twice — in cancer drugs  pm july    investors business daily can biomarin bmrn keep the earnings streak alive in q  am july    zackscom whats in store for endocyte ecyt this earnings season  am july    zackscom aveo pharmaceuticals aveo q earnings whats in store  am july    zackscom biotech bonanza the next leg up  pm july    seeking alpha hershey trust co buys eagle pharmaceuticals inc momo inc clovis oncology inc sells atlassian   pm july    gurufocuscom whats in the cards for merck kgaa mkgaf in q earnings  am july    zackscom  stocks at week highs still worth buying  am july    motley fool could q surprise spike this beleaguered biotechs stock  pm july    investors business daily gilead could acquire this biotech — but vertex is still better analyst  pm july    investors business daily clovis clvs focuses on rubraca launch and label expansion  pm july    zackscom heres why clovis oncology inc jumped  in june  am july    motley fool this rebounding pharma stock may launch another breakout move  pm june    investors business daily gilead and vertex should join — but dont hold your breath analyst  pm june    investors business daily  stocks that turned  into at least  in just one year  am june    motley fool is it too late to buy clovis oncology stock  pm june    motley fool will abbvie outsmart biosimilars and can clovis win the parp race  am june    motley fool is clovis oncology a takeover candidate  pm june    seeking alpha loading more headlines at a glance clovis oncology inc  flatiron parkway suite  boulder colorado  phone   industry biotechnology sector health carelife sciences fiscal yearend  view sec filings revenue  net income m employees  annual report for clvs newspressreleasecompanyusclvs press releases on clvs technical snapshots for these biotech stocks  exelixis celldex therapeutics clovis oncology and geron  am july    pr newswire  prf clovis oncology to announce second quarter  financial results and host webcast conference call on august   am july    businesswire  bzx clovis oncology announces exercise in full of underwriters’ option to purchase additional shares of common stock  pm june    businesswire  bzx biopharma stock breakouts with significant developments and market activity  pm june    pr newswire  prf key pharma stocks with advanced developments and breakthrough discoveries  am june    pr newswire  prf clovis oncology announces upsizing and pricing of public offering of common stock  pm june    businesswire  bzx todays research reports on stocks to watch clovis oncology and valeant pharmaceuticals  am june    accesswire clovis oncology announces proposed offering of common stock  pm june    businesswire  bzx sienna biopharmaceuticals appoints erle mast former cfo and cofounder of clovis oncology to board of directors  am june    globenewswire clovis oncology announces presentations at  asco annual meeting  am may    businesswire  bzx investor network clovis oncology inc to host earnings call  am may    accesswire myriad genetics and clovis oncology sign agreement for use of fdaapproved bracanalysis cdxr test to identify patients with germline brca mutations for rubracar rucaparib treatment  am april    globenewswire clovis oncology to announce first quarter  financial results and host webcast conference call on may   am april    businesswire  bzx todays research reports on biotech stocks to watch nektar therapeutics and clovis oncology  am april    accesswire research reports initiation on biotech stocks  sarepta therapeutics galena biopharma anthera pharma and clovis oncology  am april    pr newswire  prf global oncology market gains ground driven by innovative cancer treatment therapies  am april    pr newswire  prf pancreatic cancer treatment market analysis by affected region exocrine endocrine by type chemotherapy targeted therapy others by region north america europe asia pacific latin america and mea and segment forecasts     pm march    pr newswire  prf shareholder alert law office of brodsky  smith llc announces investigation of the board of directors of clovis oncology inc  clvs  pm march    accesswire  biotech companies set for major breakouts in   am march    pr newswire  prf biotech stocks under scanner  acadia pharma clovis oncology galena biopharma and northwest biotherapeutics  am feb    pr newswire  prf loading more headlines trending tickers quoteszigmancomposite vuzi quoteszigmancomposite jcp quoteszigmancomposite nugt quoteszigmancomposite tlt quoteszigmancomposite jnug x powered by log in  am edt july   marketstatecountryus new york pre marketstatecountryuk london open marketstatecountryjp tokyo closed marketstatecountryus   marketstatecountryuk   marketstatecountryjp   view all latest news newslatest aset yourself up to get the most out of retirement aeuropean stocks sell off as ubs falls tech worries weigh aprince william and kate middleton are hiring— though not for these weird five royal family jobs arightmove profit rises on ad sales abank of ireland profit falls to restart dividend ahow do i get a reverse mortgage aus tech stocks shape up for another day of selling after amazon disappoints athis city’s subway system will soon run entirely on renewable energy a‘skinny’ repeal of obamacare fails to pass in latenight senate vote aubs credit suisse profit up after strategic shift arenault firsthalf profit leaps on higher volume aftse  under pressure as bt pushed lower afrances cac  falls  dropping further in early friday trade abarclays falls  after earnings report abritish airways parent iag rises  after quarterly profit report abritish airways parent iags profit soars agermanys dax opens  lower at  afrances cac  opens  lower at  alinde profit slides on restructuring costs auks ftse  opens  lower at  loading more headlines dow quoteszigmanrealtime    nasdaq quoteszigmanrealtime    sp  quoteszigmanrealtime    kiosk   the retirementors retirement advice from our industry experts our team of financial professionals can help you plan and save for retirement then live well in it congakioskretirementorshtml    alerts congakioskalertshtml    virtual stock exchange our free stockmarket game • trade your virtual portfolio in real time • talk strategies in group discussions • find or create a game that suits you • use our learning center to improve congakioskgameshtml    location scouts housingmarket insights from our realty pros plus the latest data from realtorcom on  home markets across the us • see our complete real estate site congakioskrealestatehtml    lazy portfolios set it and forget it check out the returns on our  lazy portfolios that are made up of lowcost buyandhold index funds • how to create your own lazy portfolio congakiosklazyportfoliohtml  marketwatchcom site index topics help feedback newsroom roster media archive premium products mobile company info code of conduct corrections advertising media kit advertise locally reprints  licensing broker center your ad choices follow marketwatch rss podcasts wsjcom barrons online bigcharts virtual stock exchange financial news london wsjcom small business realtorcom mansion global copyright   marketwatch inc all rights reserved by using this site you agree to the terms of service privacy policy and cookie policy intraday data provided by six financial information and subject to terms of use historical and current endofday data provided by six financial information all quotes are in local exchange time realtime last sale data for us stock quotes reflect trades reported through nasdaq only intraday data delayed at least  minutes or per exchange requirements marketwatch top stories link to marketwatchs slice  clovis oncology inc nasdaqclvs clovis oncology inc clvs product news news  stocknewscom     follow us stocktwits twitter clovis oncology inc clvs product news news clvs – clovis reported a solid slate of progressionfree survival data for its parp drug rubraca rucaparib that will help it line up right alongside rivals in the field possibly eliminating an advantage held by tesaro for access to a wider group of ovarian cancer patients jun    am  by stocknewscom staff product news read more about this news itemclovis soars as a new round of phiii rubraca data looks promising — but roci scandal bites again with m settlementshares of clovis oncology soared  monday morning after the biotech reported a solid slate of progressionfree survival data for its parp drug rubraca rucaparib that will help it line up right alongside rivals in the field possibly eliminating an advantage held by tesaro for access to a wider groupfrom clvs at a glance clvs current powr rating™ overall powr rating™ clvs current price   more clvs ratings data and news clvs price reaction the day of this event jun  clvs closing price clvs volume from avgleading up to this eventclvs mo returnafter this eventclvs day returnclvs day returnclvs day return clvs price chart more clovis oncology inc clvs news view all eventdate symbol news detail start price end price change powr rating loading please wait view all clvs news page generated in  seconds clovis oncology inc  product pipeline review      about us blog contact us faq  usd eur gbp usd ▼ usd eur gbp € eur  usd £ gbp rest of world us toll free  advanced price from €eurusd£gbp view pricing home  categories  company reports select a format  €eurusd£gbp single user electronic pdf  this is a single user license allowing one specific user access to the product the report will be emailed to you the report is sent in pdf format  €eurusd£gbp site license electronic pdf  this is a site license allowing all users within a given geographical location of your organisation access to the product the report will be emailed to you the report is sent in pdf format  €eurusd£gbp enterprisewide electronic pdf  this is an enterprise license allowing all employees within your organisation access to the product the report will be emailed to you the report is sent in pdf format  add to basket order by fax need a quote  our clients have a question email us view faqs recently viewed products partner of research and marketsvaccinating  children in  why choose research and markets worlds largest selection trusted by the best customer focused safe  secure thanks so much you get  stars for the fastest turn around nancy strisik sr administrative assistant to sr director mark fraga global strategic marketing sanofi clovis oncology inc  product pipeline review   id  company profile april   pages global markets direct clovis oncology description table of contents samples formats  of  login to access executive summary printer friendly printable pdf brochure send to a friend clovis oncology inc  product pipeline review  summaryglobal markets direct’s ‘clovis oncology inc  product pipeline review  ’ provides an overview of the clovis oncology inc’s pharmaceutical research and development focusthis report provides comprehensive information on the current therapeutic developmental pipeline of clovis oncology inc’s complete with comparative analysis at various stages therapeutics assessment by drug target mechanism of action moa route of administration roa and molecule type it also reviews latest updates and featured news and press releases along with special features on latestage and discontinued projectsglobal markets direct’s report features investigational drugs from across globe covering over  therapy areas and nearly  indications the report is built using data and information sourced from global markets direct’s proprietary databases companyuniversity websites sec filings investor presentations and featured press releases from companyuniversity sites and industryspecific third party sources put together by global markets direct’s team drug profilesrecords featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information additionally processes including live news  deals tracking browser based alertbox and clinical trials registries tracking ensure that the most recent developments are captured on a real time basisthe report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage it strengthens rd pipelines by identifying new targets and moas to produce firstinclass and bestinclass productsnote certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated diseasescope the report provides brief overview of clovis oncology inc including business description key information and facts and its locations and subsidiaries the report reviews current pipeline of clovis oncology inc’s human therapeutic division and enlists all their major and minor projects the report features product description and descriptive mechanism of action for key pipeline products along with the product’s developmental history and major milestones special feature on outlicensed and partnered product portfolio the report summarizes all the dormant and discontinued pipeline projects latest company statement latest news and deals relating to the clovis oncology inc’s pipeline productsreasons to buy evaluate clovis oncology inc’s strategic position with total access to detailed information on its product pipeline assess the growth potential of clovis oncology inc in its therapy areas of focus identify new drug targets and therapeutic classes in the clovis oncology inc’s rd portfolio and develop key strategic initiatives to reinforce pipeline in those areas exploit inlicensing opportunities by identifying windows of opportunity to fill portfolio gaps develop strategic initiatives by understanding the focus areas of clovis oncology inc and exploit collaboration and partnership opportunities identify emerging players with potentially strong product portfolio and create effective counterstrategies to gain competitive advantage plan mergers and acquisitions effectively by identifying the most promising pipeline of clovis oncology inc develop and design inlicensing and outlicensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope explore the dormant and discontinued projects of clovis oncology inc and identify potential opportunities in those areas avoid intellectual property rights related issues show less read more note product cover images may vary from those shown  of  login to access executive summary printer friendly printable pdf brochure send to a friend table of contentstable of contentslist of tableslist of figuresclovis oncology inc snapshotclovis oncology inc overviewkey informationkey factsclovis oncology inc  research and development overviewkey therapeutic areasclovis oncology inc  pipeline reviewpipeline products by stage of developmentpipeline products  monotherapypipeline products  partnered productspartnered productscombination treatment modalitiesclovis oncology inc  pipeline products glanceclovis oncology inc  late stage pipeline productsphase iii productscombination treatment modalitiesclovis oncology inc  clinical stage pipeline productsphase ii productscombination treatment modalitiesphase i productscombination treatment modalitiesclovis oncology inc  early stage pipeline productsdiscovery productscombination treatment modalitiesclovis oncology inc  drug profilesrucaparib phosphateproduct descriptionmechanism of actionrd progresscoproduct descriptionmechanism of actionrd progresslucitanibproduct descriptionmechanism of actionrd progressmutant ckit inhibitorproduct descriptionmechanism of actionrd progressclovis oncology inc  pipeline analysisclovis oncology inc  pipeline products by targetclovis oncology inc  pipeline products by route of administrationclovis oncology inc  pipeline products by molecule typeclovis oncology inc  pipeline products by mechanism of actionclovis oncology inc  recent pipeline updatesclovis oncology inc  company statementclovis oncology inc  locations and subsidiarieshead officeother locations  subsidiariesappendixmethodologycoveragesecondary researchprimary researchexpert panel validationcontact usdisclaimer list of tablesclovis oncology inc key informationclovis oncology inc key factsclovis oncology inc  pipeline by indication clovis oncology inc  pipeline by stage of development clovis oncology inc  monotherapy products in pipeline clovis oncology inc  partnered products in pipeline clovis oncology inc  partnered products combination treatment modalities clovis oncology inc  phase iii clovis oncology inc  phase ii clovis oncology inc  phase i clovis oncology inc  discovery clovis oncology inc  pipeline by target clovis oncology inc  pipeline by route of administration clovis oncology inc  pipeline by molecule type clovis oncology inc  pipeline products by mechanism of action clovis oncology inc  recent pipeline updates clovis oncology inc other locationsclovis oncology inc subsidiaries list of figuresclovis oncology inc  pipeline by top  indication clovis oncology inc  pipeline by stage of development clovis oncology inc  monotherapy products in pipeline clovis oncology inc  partnered products in pipeline clovis oncology inc  pipeline by top  target clovis oncology inc  pipeline by top  route of administration clovis oncology inc  pipeline by top  molecule type clovis oncology inc  pipeline products by top  mechanism of action   note product cover images may vary from those shown  of  loading  of  note product cover images may vary from those shown related products clovis oncology inc clvs  financial and strategic swot analysis review  swot analysis july  from €eurusd£gbp ziopharm oncology inc  product pipeline review    company profile july  from €eurusd£gbp oncology research international limited  product pipeline review    company profile december  region global from €eurusd£gbp sentinel oncology limited  product pipeline review    company profile august  from €eurusd£gbp sentinel oncology limited  product pipeline review    company profile october  from €eurusd£gbp stemline therapeutics inc  product pipeline review    company profile august  from €eurusd£gbp agenus inc  product pipeline review    company profile april  from €eurusd£gbp sorrento therapeutics inc  product pipeline review    company profile june  from €eurusd£gbp cytomx therapeutics inc  product pipeline review    company profile june  from €eurusd£gbp mersana therapeutics inc  product pipeline review    company profile september  from €eurusd£gbp close clovis oncology inc  product pipeline review   close ask a question required information product clovis oncology inc  product pipeline review   your question your contact details title mr mrs dr miss ms prof first name last name email address country please select  united states united kingdom germany canada australia  afghanistan albania algeria american samoa andorra angola anguilla antarcticacasey antarcticascott antigua and barbuda argentina armenia aruba ascension island ashmore and cartier islands atlantic east atlantic west australia austria azerbaijan bahamas bahrain bangladesh barbados belarus belgium belize benin bermuda bhutan bolivia bosnia and herzegovina botswana brazil british virgin islands brunei bulgaria burkina faso burma burundi cambodia cameroon canada cape verde cayman islands central african republic chad chile china christmas island clipperton island cocos keeling islands colombia comoros congo cook islands costa rica croatia cuba curaco cyprus czech republic democratic republic of congo denmark djibouti dominica dominican republic east timor ecuador egypt el salvador equatorial guinea eritrea estonia ethiopia falkland islands islas malvinas faroe islands fiji islands finland france french guiana french polynesia gabon gambia gaza strip georgia germany ghana gibraltar greece greenland grenada guadeloupe guam guatemala guinea guineabissau guyana haiti honduras hong kong hungary iceland india indonesia iran iraq ireland israel italy ivory coast ivory coast cote divoire jamaica japan jordan kazakhstan kenya kiribati kosovo kuwait kyrgyzstan laos latvia lebanon lesotho liberia libya liechtenstein lithuania luxembourg macau macedonia madagascar malawi malaysia maldives mali malta marshall islands martinique mauritania mauritius mayotte islands mexico micronesia moldova monaco mongolia montenegro montserrat morocco mozambique myanmar namibia nauru nepal netherlands netherlands antilles new caledonia new zealand nicaragua niger nigeria niue norfolk islands north korea northern ireland northern marianas norway oman pakistan palau palestine panama papua new guinea paraguay peru philippines poland portugal puerto rico qatar reunion romania russia rwanda saint christopher nevis saint helena saint kitts and nevis saint lucia saint martin saint vincent and the grenadines samoa san marino sao tome saudi arabia scotland senegal serbia serbia and montenegro seychelles sierra leone singapore sint maarten slovakia slovenia solomon islands somalia south africa south korea spain sri lanka sudan suriname swaziland sweden switzerland syria tahiti taiwan tajikistan tanzania thailand togo trinidad and tobago tunisia turkey turkmenistan turks and caicos islands tuvalu uganda ukraine united arab emirates united kingdom united states uruguay uzbekistan vanuatu vatican city holy see venezuela vietnam virgin islands wallis and futuna west bank west indies western sahara yemen yugoslavia zaire zambia zimbabwe phone number                                                                                                                                                                                                                                    we request your telephone number so we can contact you in the event we have difficulty reaching you via email we aim to respond to all questions on the same business day close send to a friend  required information friends details full name email address message to friend your contact details full name email address close request a quote please complete the below form and click send request to obtain a pdf quotation and order form this document will be available for immediate download and will also be emailed to you  required information your address address  address  address  city postalzip code country please select  united states united kingdom germany canada australia  afghanistan albania algeria american samoa andorra angola anguilla antarcticacasey antarcticascott antigua and barbuda argentina armenia aruba ascension island ashmore and cartier islands atlantic east atlantic west australia austria azerbaijan bahamas bahrain bangladesh barbados belarus belgium belize benin bermuda bhutan bolivia bosnia and herzegovina botswana brazil british virgin islands brunei bulgaria burkina faso burma burundi cambodia cameroon canada cape verde cayman islands central african republic chad chile china christmas island clipperton island cocos keeling islands colombia comoros congo cook islands costa rica croatia cuba curaco cyprus czech republic democratic republic of congo denmark djibouti dominica dominican republic east timor ecuador egypt el salvador equatorial guinea eritrea estonia ethiopia falkland islands islas malvinas faroe islands fiji islands finland france french guiana french polynesia gabon gambia gaza strip georgia germany ghana gibraltar greece greenland grenada guadeloupe guam guatemala guinea guineabissau guyana haiti honduras hong kong hungary iceland india indonesia iran iraq ireland israel italy ivory coast ivory coast cote divoire jamaica japan jordan kazakhstan kenya kiribati kosovo kuwait kyrgyzstan laos latvia lebanon lesotho liberia libya liechtenstein lithuania luxembourg macau macedonia madagascar malawi malaysia maldives mali malta marshall islands martinique mauritania mauritius mayotte islands mexico micronesia moldova monaco mongolia montenegro montserrat morocco mozambique myanmar namibia nauru nepal netherlands netherlands antilles new caledonia new zealand nicaragua niger nigeria niue norfolk islands north korea northern ireland northern marianas norway oman pakistan palau palestine panama papua new guinea paraguay peru philippines poland portugal puerto rico qatar reunion romania russia rwanda saint christopher nevis saint helena saint kitts and nevis saint lucia saint martin saint vincent and the grenadines samoa san marino sao tome saudi arabia scotland senegal serbia serbia and montenegro seychelles sierra leone singapore sint maarten slovakia slovenia solomon islands somalia south africa south korea spain sri lanka sudan suriname swaziland sweden switzerland syria tahiti taiwan tajikistan tanzania thailand togo trinidad and tobago tunisia turkey turkmenistan turks and caicos islands tuvalu uganda ukraine united arab emirates united kingdom united states uruguay uzbekistan vanuatu vatican city holy see venezuela vietnam virgin islands wallis and futuna west bank west indies western sahara yemen yugoslavia zaire zambia zimbabwe state your details title mr mrs dr miss ms prof first name last name organisation email address phone number                                                                                                                                                                                                                                    po number if applicable product format license format properties price single user electronic pdf the report will be emailed to you the report is sent in pdf format this is a single user license allowing one specific user access to the product €eurusd£gbp site license electronic pdf the report will be emailed to you the report is sent in pdf format this is a site license allowing all users within a given geographical location of your organisation access to the product €eurusd£gbp enterprisewide electronic pdf the report will be emailed to you the report is sent in pdf format this is an enterprise license allowing all employees within your organisation access to the product €eurusd£gbp  the price quoted above is only valid for  days please submit your order within that time frame to avail of this price as all prices are subject to change clovis oncology  investors  news  overviewhomeabout clovisleadershipproductspipelinepatients  caregiversbusiness developmentinvestors  news overview corporate governance sec filings stock information news releases webcasts  presentations annual meeting materials event calendar information request investor faqgrants  researchcareerscontactprintemailrss feedsemail alertsir contactsfinancial tear sheetoverviewwebcastq  clovis oncology inc earnings conference call live at  pm etq  clovis oncology inc earnings conference callwednesday august    pm et  webcast presentation helpclick here for webcastadd to calendar help javascript must be enabled to use this feature  click here to add this event to your calendar corporate profile clovis oncology is a biopharmaceutical company focused on acquiring developing and commercializing cancer treatments in the united states europe and other international markets clovis’ development programs are targeted at specific subsets of cancer combining precision medicine with companion diagnostics to direct therapeutics to those patients most likely to benefit from their use clovis believes this approach to precision medicine – to deliver the right drmore stock chart stock quote clvs common stock exchangenasdaq gs us dollarpricechange    intraday highintraday lowvolumedata as of   pm etminimum  minute delayrefresh quoterecent newsmore datetitle  clovis oncology to announce second quarter  financial results and host webcast conference call on august boulder colobusiness wirejul   clovis oncology inc nasdaq clvs will announce its second quarter  financial results on wednesday august   after the close of the us financial markets clovis’ senior management will host a conference call and live audio webcast at  pm et that day to discuss the company’s results in greater detail the conference call is being webcast and can be accessed from the clovis  clovis oncology announces exercise in full of underwriters’ option to purchase additional shares of common stockboulder colobusiness wirejun   clovis oncology inc nasdaqclvs announced today that the underwriters of its recently announced public offering of its common stock have exercised in full their option to purchase an additional  shares the offering including the sale of the additional shares is expected to close on june   subject to customary closing conditions clovis oncology intends to use th clovis oncology announces upsizing and pricing of public offering of common stockboulder colobusiness wirejun   clovis oncology inc nasdaqclvs announced today the pricing of an underwritten public offering of  shares of its common stock at  per share before underwriting discounts and commissions the size of the offering was upsized from  million to  million in addition the underwriters have a day option to purchase up to an additional  shares of common stock from clovis onco upcoming eventsmore datetitle pm etq  clovis oncology inc earnings conference call receive email alertssign up to receive email alerts whenever clovis oncology inc posts new information to the site just enter your email address and click submit  replication or redistribution of edgar online inc content is expressly prohibited without the prior written consent of edgar online inc edgar online inc shall not be liable for any errors or delays in the content or for any actions taken in reliance thereon copyright   clovis oncology all rights reserved contact  terms of use  privacy policy  sitemap